{"meta":{"query_hash":"458495b2c95b","filters":{"venue":"Targeted Oncology"},"cohort_total":57,"direct_labels_cover":0,"predictions_cover":57,"exported":57,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/458495b2c95b","api":"https://metacan.xera.ac/api/v1/cohort?venue=Targeted+Oncology"},"results":[{"id":"W1627803359","doi":"10.1007/s11523-015-0386-5","title":"Simultaneous Targeting of Bladder Tumor Growth, Survival, and Epithelial-to-Mesenchymal Transition with a Novel Therapeutic Combination of Acetazolamide (AZ) and Sulforaphane (SFN)","year":2015,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Genomics, phytochemicals, and oxidative stress","field":"Biochemistry, Genetics and Molecular Biology","cited_by":55,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Cancer research; Sulforaphane; Protein kinase B; PI3K/AKT/mTOR pathway; Clonogenic assay; Apoptosis; Bladder cancer; Epithelial–mesenchymal transition; Survivin; Pharmacology; Cancer; Internal medicine; Chemistry; Metastasis; Biochemistry","score_opus":0.013589086711456975,"score_gpt":0.25220228280851553,"score_spread":0.23861319609705856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1627803359","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919531,0.000636985,0.006452534,0.00024981858,0.000072209325,0.00033409463,0.000120574245,0.00000814193,0.00017259526],"genre_scores_gemma":[0.9964445,0.00007894139,0.0030852875,0.00013588763,0.000060053047,0.000013929514,0.0001388391,0.000022058895,0.000020504449],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989416,0.00009736388,0.00029810084,0.0003215154,0.00011947623,0.00022191484],"domain_scores_gemma":[0.9990661,0.00008548232,0.0001960929,0.00013501513,0.0003922556,0.00012501415],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002787308,0.0001755629,0.00035689547,0.00007556977,0.000034975787,0.0000058562014,0.000097704695,0.00014559808,0.000005271632],"category_scores_gemma":[0.00018057087,0.00015779915,0.00003485583,0.00010826641,0.00028659307,0.0000077049435,0.000053557178,0.00009035424,5.945279e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009793129,0.00020341546,0.0011775194,0.000052992847,0.00010606584,0.000004138152,0.00068138854,0.00024083226,0.9958898,0.00016251073,0.000028975533,0.0004730853],"study_design_scores_gemma":[0.0036526595,0.003448374,0.0025704512,0.000019087513,0.00008380691,0.000039739658,0.0013040416,0.0006250959,0.9868835,0.0005339225,0.0005819668,0.00025732873],"about_ca_topic_score_codex":0.00006735767,"about_ca_topic_score_gemma":0.000052728985,"teacher_disagreement_score":0.009006238,"about_ca_system_score_codex":0.000018511892,"about_ca_system_score_gemma":0.00012077235,"threshold_uncertainty_score":0.64348626},"labels":[],"label_agreement":null},{"id":"W1967370517","doi":"10.1007/s11523-014-0356-3","title":"Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy","year":2015,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Medicine; Renal cell carcinoma; Internal medicine; Neutrophilia; Lymphocytopenia; Nephrectomy; Sunitinib; Oncology; Univariate analysis; Gastroenterology; Neutrophil to lymphocyte ratio; Targeted therapy; Multivariate analysis; Cancer; Lymphocyte; Kidney","score_opus":0.013345270174694153,"score_gpt":0.24004238192754693,"score_spread":0.2266971117528528,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1967370517","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99475706,0.0013263903,0.000024201963,0.000079230704,0.00009572449,0.0021144424,0.000048871425,0.00009476824,0.001459321],"genre_scores_gemma":[0.9951711,0.000020396716,0.004043411,0.000090578054,0.00002933873,0.00017437339,0.0003075627,0.00007732237,0.00008590011],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99732906,0.00035123393,0.0006441796,0.0004970698,0.00047292092,0.0007055339],"domain_scores_gemma":[0.99791175,0.00014411732,0.00047091083,0.00044623145,0.0006685954,0.0003583841],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00033333985,0.00036255052,0.0007853097,0.00034938598,0.0000529464,0.000008980079,0.00015456515,0.00025188277,0.00008998487],"category_scores_gemma":[0.00012753524,0.00026630118,0.0000662799,0.00079860387,0.00039256611,0.00012474519,0.00004182093,0.0003501934,0.0000123174705],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025471538,0.0015530041,0.94953215,0.000088167384,0.00016425391,0.0003702706,0.00095873256,0.000044654713,0.0204107,0.000002932344,0.00015436727,0.0012492063],"study_design_scores_gemma":[0.022934744,0.009325909,0.9261514,0.00015459543,0.00017658375,0.0000063622106,0.00023726544,0.0001382589,0.040158723,0.000011448806,0.00039692153,0.00030776384],"about_ca_topic_score_codex":0.0002764193,"about_ca_topic_score_gemma":0.00003721897,"teacher_disagreement_score":0.02338075,"about_ca_system_score_codex":0.00055729283,"about_ca_system_score_gemma":0.001257771,"threshold_uncertainty_score":0.9999789},"labels":[],"label_agreement":null},{"id":"W1973375841","doi":"10.1007/s11523-009-0120-2","title":"Nuclear imaging of molecular processes in cancer","year":2009,"lang":"en","type":"review","venue":"Targeted Oncology","topic":"Medical Imaging Techniques and Applications","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"University College London Hospitals NHS Foundation Trust; National Institute for Health and Care Research; Cancer Research UK","keywords":"Molecular imaging; Medicine; Positron emission tomography; Nuclear medicine; Nuclear imaging; Pet imaging; Medical physics; Cancer; Internal medicine; In vivo; Biology; Biotechnology","score_opus":0.04336537521571856,"score_gpt":0.42497326225833704,"score_spread":0.3816078870426185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1973375841","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00002542497,0.99441993,0.000089259396,0.0019013416,0.0000321036,0.00081495685,0.000012980787,0.000094496376,0.0026095137],"genre_scores_gemma":[0.00013051463,0.9908784,0.0077809785,0.0007607522,0.00006608477,0.00020825675,0.00006995605,0.000039252147,0.00006577723],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987114,0.00006384004,0.0005705076,0.0002884012,0.0001332651,0.00023259061],"domain_scores_gemma":[0.9991448,0.000077248194,0.00029118254,0.00028164702,0.00010343106,0.00010168678],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015910185,0.00019759919,0.0015092219,0.00023864348,0.0000141493665,0.0000027485362,0.00018696407,0.00024190989,0.00027963586],"category_scores_gemma":[0.00019505442,0.0001586122,0.00014609536,0.00057556294,0.000121767946,0.000017301825,0.000046399713,0.0005157337,0.000014155885],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000005372384,0.00024476126,0.000010193837,0.010140583,0.000028552604,0.000118744225,0.000030914543,1.08041036e-7,0.00010066422,0.0002517707,0.00554525,0.9835231],"study_design_scores_gemma":[0.00021109355,0.00009600501,0.000004348927,0.008372205,0.00043181193,0.0000841502,0.0000055612354,0.00001997493,0.00004271664,0.00018788404,0.99042267,0.00012159671],"about_ca_topic_score_codex":0.00007945729,"about_ca_topic_score_gemma":0.000005136896,"teacher_disagreement_score":0.9848774,"about_ca_system_score_codex":0.00022673888,"about_ca_system_score_gemma":0.0011900916,"threshold_uncertainty_score":0.64680177},"labels":[],"label_agreement":null},{"id":"W1980810683","doi":"10.1007/s11523-007-0042-9","title":"Second-line therapy with gefitinib in combination with docetaxel for advanced non-small cell lung cancer: a phase II randomized study","year":2007,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ste. Anne's Hospital","funders":"National Cancer Institute; World Health Organization","keywords":"Docetaxel; Medicine; Gefitinib; Internal medicine; Lung cancer; Chemotherapy; Oncology; Combination therapy; Adverse effect; Rash; Cancer; Epidermal growth factor receptor","score_opus":0.013741353526704404,"score_gpt":0.3733654310320024,"score_spread":0.359624077505298,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1980810683","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9807699,0.0012485387,0.005572032,0.0006347677,0.00014783697,0.009187584,0.000039586357,0.000056022876,0.0023437608],"genre_scores_gemma":[0.9885989,0.00011787494,0.006316091,0.0006186607,0.00007964971,0.0026522952,0.00021239503,0.000043072905,0.0013610584],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99861294,0.00007200992,0.0004309144,0.00036261295,0.00014119185,0.00038031756],"domain_scores_gemma":[0.9988188,0.0003398481,0.0002648326,0.00018521897,0.0002751122,0.000116147545],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052916317,0.00023424745,0.00086431025,0.0002229526,0.00012955969,0.000006746282,0.00006536022,0.00009821825,0.00017274279],"category_scores_gemma":[0.000022232596,0.00015167047,0.00006875884,0.0003079906,0.00007640886,0.00007661715,0.000011138047,0.00017950682,9.733042e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8425724,0.034681898,0.019020805,0.00023018007,0.0020126023,0.00047414063,0.02389068,0.00048875547,0.010559075,0.00015692654,0.00038024178,0.0655323],"study_design_scores_gemma":[0.94866174,0.03443628,0.003401035,0.00007282327,0.000794697,0.000017864677,0.0018830769,0.0010678843,0.006155689,0.000042399326,0.003240324,0.00022617388],"about_ca_topic_score_codex":0.00021295175,"about_ca_topic_score_gemma":0.0027784505,"teacher_disagreement_score":0.10608935,"about_ca_system_score_codex":0.00046113948,"about_ca_system_score_gemma":0.00070008414,"threshold_uncertainty_score":0.61849415},"labels":[],"label_agreement":null},{"id":"W1999755104","doi":"10.1007/s11523-014-0308-y","title":"Transforming growth factor-beta and its implication in the malignancy of gliomas","year":2014,"lang":"en","type":"review","venue":"Targeted Oncology","topic":"TGF-β signaling in diseases","field":"Biochemistry, Genetics and Molecular Biology","cited_by":66,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"Glioma; Medicine; Cancer research; Malignancy; Transforming growth factor beta; Angiogenesis; Cytokine; Growth factor; Transforming growth factor; Pathology; Hepatocyte growth factor; Immunology; Internal medicine; Receptor","score_opus":0.029328501467559887,"score_gpt":0.33678045228020836,"score_spread":0.3074519508126485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1999755104","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007237243,0.9914206,0.00009786119,0.000030436191,0.00007335375,0.0007031624,0.00007795995,0.000008627841,0.00035071187],"genre_scores_gemma":[0.08023856,0.9187873,0.000079385,0.00005307128,0.00015258447,0.00018566777,0.00044757818,0.00003658581,0.00001928465],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99832124,0.0003826739,0.00056472135,0.0003852074,0.00010084814,0.00024533976],"domain_scores_gemma":[0.9991084,0.00012992603,0.00033651228,0.00030560276,0.000068175475,0.00005140011],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002871067,0.00026748684,0.0008064878,0.00012496108,0.000041111925,0.0000072929997,0.00040772773,0.0005483898,0.000015045696],"category_scores_gemma":[0.000108220745,0.0001933824,0.00018845046,0.00017066655,0.00007535652,0.0000030642782,0.00005868645,0.0001752918,0.000005538775],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000061943225,0.00032333154,0.00011998545,0.015377376,0.00030712524,0.000018954244,0.0003671274,0.0000014241285,0.04026325,0.0018304707,0.00034698407,0.94098204],"study_design_scores_gemma":[0.0003463441,0.00038031075,0.00013304791,0.00070591946,0.00025617945,0.00006206381,0.000017161088,0.0000013103906,0.008027805,0.00006468488,0.989728,0.00027720295],"about_ca_topic_score_codex":0.000009409779,"about_ca_topic_score_gemma":0.000020563812,"teacher_disagreement_score":0.989381,"about_ca_system_score_codex":0.000028537615,"about_ca_system_score_gemma":0.00030357964,"threshold_uncertainty_score":0.7885905},"labels":[],"label_agreement":null},{"id":"W2021963511","doi":"10.1007/s11523-008-0093-6","title":"Mechanisms of resistance to EGFR tyrosine kinase inhibitors: implications for patient selection and drug combination strategies","year":2008,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Parks and Wilderness Society","funders":"","keywords":"Medicine; Cetuximab; Epidermal growth factor receptor; EGFR inhibitors; Tyrosine kinase; Lung cancer; Cancer; Colorectal cancer; Cancer research; Drug resistance; Gefitinib; Erlotinib; Signal transduction; Targeted therapy; Receptor tyrosine kinase; Bioinformatics; Oncology; Internal medicine; Receptor; Biology","score_opus":0.013520744220156556,"score_gpt":0.3217577086328896,"score_spread":0.30823696441273307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2021963511","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96678156,0.00051300204,0.020210128,0.009035636,0.00018351682,0.0016590435,0.00009145134,0.00006713155,0.0014585148],"genre_scores_gemma":[0.9845944,0.000031740285,0.014319806,0.00024425946,0.000025340129,0.000332282,0.00012131994,0.000010890075,0.00031996318],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9994351,0.000022684673,0.00020246935,0.00016352374,0.000059275797,0.00011689093],"domain_scores_gemma":[0.9994079,0.000059171325,0.00009747549,0.00008657415,0.000278791,0.00007009793],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000048147147,0.000076596625,0.00017755589,0.00010437945,0.00013162314,0.000003629713,0.000019817639,0.000054433167,0.0000101159385],"category_scores_gemma":[0.000040587092,0.000069882575,0.000028535982,0.00018940581,0.000036686863,0.00006556516,0.000009765346,0.00004068105,0.0000014071944],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015838747,0.002939438,0.0053506987,0.00033008322,0.00035977532,0.000012545373,0.011949947,0.00020999716,0.70521665,0.2102399,0.040896647,0.020910427],"study_design_scores_gemma":[0.019954778,0.018471079,0.31821185,0.0002918692,0.0012570127,0.00019884671,0.007284769,0.00035186,0.44717315,0.10006853,0.085984565,0.0007517035],"about_ca_topic_score_codex":0.00006621027,"about_ca_topic_score_gemma":0.00019629113,"teacher_disagreement_score":0.31286114,"about_ca_system_score_codex":0.00023406702,"about_ca_system_score_gemma":0.00028900598,"threshold_uncertainty_score":0.28497285},"labels":[],"label_agreement":null},{"id":"W2037096531","doi":"10.1007/s11523-012-0252-7","title":"The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients","year":2013,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; BC Cancer Agency; Princess Margaret Cancer Centre; University of Toronto; London Health Sciences Centre; University of Alberta; Queen Elizabeth II Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Cancer Institute","keywords":"Medicine; Renal cell carcinoma; Oncology; Targeted therapy; VEGF receptors; Internal medicine; Second-line therapy; Cancer; Chemotherapy","score_opus":0.07733604392423403,"score_gpt":0.3777414729966405,"score_spread":0.30040542907240647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2037096531","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98669416,0.0007377807,0.00009575522,0.0051325294,0.0011189322,0.0055363756,0.00009421642,0.000096347954,0.00049393176],"genre_scores_gemma":[0.9853859,0.0001914958,0.006204708,0.0050386093,0.00037979448,0.0007024171,0.0003185972,0.00014282313,0.0016356355],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9898507,0.0018472738,0.004654021,0.0012119934,0.0011109897,0.0013249998],"domain_scores_gemma":[0.9909801,0.0038506042,0.0017207409,0.0012423572,0.001293641,0.00091259176],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003631328,0.00080264604,0.0030027498,0.00048081102,0.00019053495,0.00004135615,0.00063222024,0.00067702436,0.0010734583],"category_scores_gemma":[0.0017778099,0.0005048224,0.00070091477,0.001065492,0.0002154967,0.0001648682,0.00017824545,0.0013356074,0.00040388602],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0073235813,0.004158712,0.9573284,0.000053343414,0.000604303,0.000112345246,0.0009024803,0.00008788848,0.0012213181,0.0000075682174,0.0030270596,0.025173001],"study_design_scores_gemma":[0.026070582,0.033232477,0.9230247,0.000033464847,0.00022227202,0.0000083304185,0.00016824514,0.00026146253,0.003604141,0.00009105735,0.012799418,0.00048383023],"about_ca_topic_score_codex":0.0008826692,"about_ca_topic_score_gemma":0.0018046224,"teacher_disagreement_score":0.03430368,"about_ca_system_score_codex":0.0011148299,"about_ca_system_score_gemma":0.00070444547,"threshold_uncertainty_score":0.9998397},"labels":[],"label_agreement":null},{"id":"W2061663237","doi":"10.1007/s11523-010-0143-8","title":"Prognostic and predictive biomarkers in renal cell carcinoma","year":2010,"lang":"en","type":"review","venue":"Targeted Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Renal cell carcinoma; Biomarker; Biomarker discovery; Kidney cancer; Vascular endothelial growth factor; Clear cell renal cell carcinoma; Oncology; Targeted therapy; Cancer; Pathology; Cancer research; Bioinformatics; Internal medicine; VEGF receptors; Proteomics; Biology; Gene","score_opus":0.03238352251163952,"score_gpt":0.3148014887375521,"score_spread":0.2824179662259126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2061663237","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009020171,0.97845834,0.000004670914,0.00006474476,0.00035596194,0.0032926293,0.000081616876,0.000051143164,0.008670705],"genre_scores_gemma":[0.007945543,0.9885826,0.0012234877,0.000053035234,0.0002620796,0.00068461185,0.0007593221,0.0001051221,0.00038417295],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99710387,0.00039941203,0.00081467925,0.00084651116,0.00023652396,0.0005990082],"domain_scores_gemma":[0.99805194,0.00060489913,0.00040327437,0.00048191837,0.00008477179,0.00037321495],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00034135158,0.0006287226,0.0026684264,0.0006857522,0.000048066275,0.000011245269,0.00015908487,0.0013120897,0.00014614726],"category_scores_gemma":[0.00018060963,0.00047511232,0.00032422252,0.0004439319,0.0002925647,0.00003865307,0.000139871,0.001394173,0.000088483815],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037883825,0.0007691244,0.0043255785,0.012304928,0.00044393033,0.005939407,0.00024375595,1.7472051e-7,0.00012828033,0.000010856151,0.001123952,0.9743312],"study_design_scores_gemma":[0.0024523982,0.0041578664,0.008332286,0.0023839641,0.00415254,0.0018077388,0.000036910413,0.000020616537,0.000057563007,0.000027711547,0.97613674,0.0004336565],"about_ca_topic_score_codex":0.00007662957,"about_ca_topic_score_gemma":0.000055025772,"teacher_disagreement_score":0.9750128,"about_ca_system_score_codex":0.00087671983,"about_ca_system_score_gemma":0.0016299031,"threshold_uncertainty_score":0.99998444},"labels":[],"label_agreement":null},{"id":"W2076911447","doi":"10.1007/s11523-013-0299-0","title":"Low level of baseline circulating VEGF-A is associated with better outcome in patients with vascular sarcomas receiving sorafenib: an ancillary study from a phase II trial","year":2013,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Vascular Tumors and Angiosarcomas","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; Institut National Du Cancer; Bayer HealthCare","keywords":"Medicine; Liter; Sorafenib; Placental growth factor; Internal medicine; Vascular endothelial growth factor; Endoglin; VEGF receptors; Angiosarcoma; Gastroenterology; Hepatocellular carcinoma; Pathology; Stem cell; CD34","score_opus":0.04767621424879121,"score_gpt":0.305364035680701,"score_spread":0.25768782143190977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2076911447","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99658465,0.000083242885,0.00022935342,0.00027531828,0.00010970444,0.002529476,0.000092052665,0.00006601558,0.000030178582],"genre_scores_gemma":[0.99583375,0.0000013091455,0.0023694627,0.0008122753,0.00015446286,0.00010192456,0.00062332465,0.00007763244,0.000025827558],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965951,0.00060599425,0.00094103016,0.00061888446,0.000683687,0.0005553469],"domain_scores_gemma":[0.99808425,0.00019330787,0.00047232167,0.00059418293,0.00043271176,0.00022325249],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00086489884,0.0003697894,0.0014009805,0.00027348733,0.00012531504,0.000014789598,0.0001794042,0.0002382566,0.0004974701],"category_scores_gemma":[0.00040381163,0.0002741297,0.00017590556,0.00052053167,0.000098610726,0.00022441336,0.000089351655,0.00048338814,0.000009175965],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005616955,0.019924859,0.9572495,0.000028584405,0.00084944867,0.000358499,0.0030237455,0.000028004979,0.0021599946,5.665554e-7,0.0001357913,0.010624025],"study_design_scores_gemma":[0.20638362,0.02288797,0.7673975,0.00018108785,0.00046292125,0.000005500759,0.0005813159,0.0014012039,0.00025688787,0.00002602995,0.000059788836,0.00035614663],"about_ca_topic_score_codex":0.0013754814,"about_ca_topic_score_gemma":0.00050786126,"teacher_disagreement_score":0.20076665,"about_ca_system_score_codex":0.00028181245,"about_ca_system_score_gemma":0.00024885425,"threshold_uncertainty_score":0.9999711},"labels":[],"label_agreement":null},{"id":"W2091875870","doi":"10.1007/s11523-013-0271-z","title":"An analysis of the treatment effect of panitumumab on overall survival from a phase 3, randomized, controlled, multicenter trial (20020408) in patients with chemotherapy refractory metastatic colorectal cancer","year":2013,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University; Amgen (Canada)","funders":"Amgen","keywords":"Panitumumab; KRAS; Medicine; Internal medicine; Hazard ratio; Oncology; Post-hoc analysis; Colorectal cancer; Randomized controlled trial; Cancer; Confidence interval","score_opus":0.009570761703216482,"score_gpt":0.31502422195572594,"score_spread":0.30545346025250947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2091875870","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99133724,0.0003650976,0.000003228911,0.00012367351,0.0002745977,0.007527321,0.0002082299,0.000011506906,0.00014908967],"genre_scores_gemma":[0.99751633,0.00017811335,0.000055203767,0.00010602586,0.00004283919,0.0019122784,0.00013259925,0.000019844629,0.000036755944],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973388,0.0010928832,0.0006726988,0.0003245264,0.00032419976,0.00024694504],"domain_scores_gemma":[0.9972518,0.001671499,0.0005572829,0.00026312718,0.00017803225,0.00007824784],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028153084,0.00031923497,0.0036615592,0.00022758925,0.000039864077,0.0000054171087,0.000087430635,0.00008634824,0.0009090595],"category_scores_gemma":[0.0001343592,0.00013780069,0.0005727966,0.00029368897,0.00021687402,0.000048814665,0.000011240766,0.00012225601,0.000001583664],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8799686,0.009560858,0.08637618,0.000009637658,0.015556252,0.0000057642483,0.0013337199,0.000096072545,0.0006372451,0.000001975273,0.000012894324,0.006440841],"study_design_scores_gemma":[0.79005647,0.040778268,0.15830624,0.000026729183,0.008052921,6.23751e-8,0.00006985471,0.0013641895,0.0012091749,0.0000037757086,0.000038775714,0.000093530696],"about_ca_topic_score_codex":0.010252994,"about_ca_topic_score_gemma":0.0036948628,"teacher_disagreement_score":0.08991208,"about_ca_system_score_codex":0.0007260682,"about_ca_system_score_gemma":0.00016312108,"threshold_uncertainty_score":0.99633783},"labels":[],"label_agreement":null},{"id":"W2201788027","doi":"10.1007/s11523-015-0396-3","title":"Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis","year":2015,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Medicine; Prostate; Adenocarcinoma; Prostate adenocarcinoma; Prostatic adenocarcinoma; Pathology; Lymphocyte; Castration; Prostate cancer; Oncology; Internal medicine; Cancer","score_opus":0.03854617420081482,"score_gpt":0.3205983842461482,"score_spread":0.28205221004533343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2201788027","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927978,0.005708605,0.000053342897,0.00028850822,0.00016489488,0.00036233966,0.00010014793,0.000043493103,0.00048090093],"genre_scores_gemma":[0.99675333,0.0002035392,0.0019828132,0.00037419438,0.000113233684,0.000042483884,0.00031770862,0.000020579322,0.0001921393],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99849606,0.00022344638,0.00042550525,0.00037722944,0.00025969424,0.00021804786],"domain_scores_gemma":[0.99891865,0.00008256857,0.00021914575,0.00036761924,0.00017905935,0.00023292491],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032285275,0.00018264461,0.0005457874,0.0002568861,0.000055062057,0.000011297275,0.00008719926,0.00018870452,0.00023566424],"category_scores_gemma":[0.00005036666,0.00015105557,0.00007360542,0.00036252636,0.00017784137,0.00011696638,0.000031501986,0.00011985935,0.000010448957],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027095536,0.00045810494,0.01514818,0.00003795163,0.0006354932,0.00021948467,0.0058912346,0.000042372994,0.9364212,0.000012135086,0.0012072597,0.01283104],"study_design_scores_gemma":[0.02086211,0.013595516,0.41939357,0.00013054667,0.0018153911,0.000035161647,0.007088773,0.00045300595,0.5180161,0.00024492727,0.017854411,0.0005104787],"about_ca_topic_score_codex":0.00083910936,"about_ca_topic_score_gemma":0.00067350996,"teacher_disagreement_score":0.41840512,"about_ca_system_score_codex":0.00030664422,"about_ca_system_score_gemma":0.00053560146,"threshold_uncertainty_score":0.61598676},"labels":[],"label_agreement":null},{"id":"W2516587078","doi":"10.1007/s11523-016-0448-3","title":"Effect of Targeting Clusterin Using OGX-011 on Antitumor Activity of Temsirolimus in a Human Renal Cell Carcinoma Model","year":2016,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Clusterin in disease pathology","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Temsirolimus; Clusterin; Medicine; Renal cell carcinoma; Pharmacology; Cancer research; Apoptosis; Downregulation and upregulation; PI3K/AKT/mTOR pathway; Internal medicine; Biology; Discovery and development of mTOR inhibitors","score_opus":0.02798368675883016,"score_gpt":0.3393615595728084,"score_spread":0.3113778728139782,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2516587078","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963496,0.00007518766,0.0007426434,0.00009984439,0.00016294076,0.0007135805,0.00004974467,0.000034538076,0.0017719348],"genre_scores_gemma":[0.9982816,0.000004420235,0.0013660203,0.000060991446,0.000095426025,0.000032386783,0.000010157874,0.000045782148,0.00010320887],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99753124,0.00064461416,0.00064087415,0.00046859495,0.00022238307,0.0004923197],"domain_scores_gemma":[0.9983289,0.0005206128,0.00045750022,0.00045633537,0.00009146457,0.00014515739],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008223639,0.00027419647,0.0011000477,0.0004505115,0.000042227875,0.0000015755652,0.00016975103,0.00030330985,0.00012138142],"category_scores_gemma":[0.00033717696,0.00020601586,0.00017069734,0.00021457905,0.00031219123,0.000060203554,0.00020301844,0.0002777958,0.000006984588],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004732091,0.0006098195,0.02939914,0.000516171,0.000020523981,0.00034348693,0.0002147506,0.0009653123,0.9612254,0.00002062233,0.00007795917,0.0018747031],"study_design_scores_gemma":[0.010573117,0.008299536,0.03617638,0.00026490362,0.00016542208,0.00009099389,0.000019917527,0.02182384,0.9222398,0.00007474575,0.000031110532,0.00024024301],"about_ca_topic_score_codex":0.00020561088,"about_ca_topic_score_gemma":0.000027585233,"teacher_disagreement_score":0.03898563,"about_ca_system_score_codex":0.00044047143,"about_ca_system_score_gemma":0.00027200946,"threshold_uncertainty_score":0.8401083},"labels":[],"label_agreement":null},{"id":"W2560844514","doi":"10.1007/s11523-016-0462-5","title":"Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial","year":2016,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Pfizer","keywords":"Medicine; Sunitinib; Placebo; Quality of life (healthcare); Neuroendocrine tumors; Internal medicine; Adverse effect; Oncology; Cancer; Pathology; Alternative medicine","score_opus":0.08123099894244132,"score_gpt":0.41849353098849157,"score_spread":0.3372625320460503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560844514","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99245644,0.000023066354,0.00005580055,0.003845325,0.00044862492,0.0019522145,0.00064190314,0.0000834261,0.00049317564],"genre_scores_gemma":[0.9968273,0.00003791597,0.0017213286,0.00027406684,0.00022511801,0.00021740171,0.0003797862,0.0000343618,0.0002827437],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.997199,0.00032993927,0.00105417,0.0005436582,0.00045887652,0.00041436453],"domain_scores_gemma":[0.99504083,0.003116392,0.00068045384,0.00045763247,0.0003714141,0.00033327605],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.00024278095,0.00022934162,0.0009255885,0.00019192713,0.000051575462,0.000009729403,0.00015233585,0.000017009374,0.0001392518],"category_scores_gemma":[0.01008897,0.00014480836,0.000082609724,0.000115571704,0.0003168042,0.00023219007,0.00008344068,0.00017090928,0.000002417041],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9668189,0.0014683957,0.008230414,0.00003099017,0.00043199194,0.0011046099,0.00011316475,0.0000015025091,0.013029042,0.00011386611,0.00039287738,0.008264218],"study_design_scores_gemma":[0.92444795,0.041857123,0.014963642,0.000068550464,0.00020223187,0.00014658064,0.00037466313,0.00007300884,0.009761002,0.00016998613,0.0076907882,0.00024449683],"about_ca_topic_score_codex":0.0005165967,"about_ca_topic_score_gemma":0.00026392718,"teacher_disagreement_score":0.042371,"about_ca_system_score_codex":0.00009180485,"about_ca_system_score_gemma":0.00038679191,"threshold_uncertainty_score":0.9982495},"labels":[],"label_agreement":null},{"id":"W2735753765","doi":"10.1007/s11523-017-0516-3","title":"A Combination of Testosterone and White Blood Cell Count as a Predictive Factor of Overall Survival in Localized Prostate Cancer","year":2017,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Hôpital Notre-Dame; McGill University; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Hazard ratio; Prostate cancer; Testosterone (patch); Internal medicine; White blood cell; Neutrophil to lymphocyte ratio; Absolute neutrophil count; Prospective cohort study; Proportional hazards model; Gastroenterology; Urology; Complete blood count; Cancer; Lymphocyte; Confidence interval; Oncology; Toxicity; Neutropenia","score_opus":0.014346547148321195,"score_gpt":0.29776721316101623,"score_spread":0.28342066601269505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2735753765","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99573493,0.00050649024,0.000007843185,0.00041868642,0.00018236776,0.0009705643,0.00016731347,0.000017851075,0.0019939514],"genre_scores_gemma":[0.9991483,0.0001655204,0.0003135138,0.000066230765,0.000020073636,0.00011121906,0.000025645435,0.00001798455,0.00013151782],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987823,0.0001280634,0.00041005638,0.00024156111,0.00022508437,0.00021293465],"domain_scores_gemma":[0.99870795,0.0000984945,0.0005321855,0.00028390856,0.00027833474,0.00009910159],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025306473,0.00014462658,0.0005455494,0.00013925438,0.00004737133,0.0000065726076,0.000111281835,0.00018148658,0.00013695493],"category_scores_gemma":[0.0002542301,0.00013430268,0.00004511801,0.000058364338,0.0003810861,0.00009869371,0.000099199075,0.00014501048,0.0000015790537],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050779656,0.0009824306,0.93677837,0.00050191866,0.00018006808,0.00007919293,0.001639515,0.0000030534766,0.05367095,0.000040688217,0.000085563894,0.00096026086],"study_design_scores_gemma":[0.015178925,0.0026031865,0.94385856,0.0002076471,0.00026299426,0.0000073508418,0.00016020906,0.0005532386,0.03658556,0.00024399595,0.00021779946,0.00012054554],"about_ca_topic_score_codex":0.00044478613,"about_ca_topic_score_gemma":0.0001674613,"teacher_disagreement_score":0.017085392,"about_ca_system_score_codex":0.00014644481,"about_ca_system_score_gemma":0.0004591978,"threshold_uncertainty_score":0.5476704},"labels":[],"label_agreement":null},{"id":"W2742486699","doi":"10.1007/s11523-017-0518-1","title":"Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars","year":2017,"lang":"en","type":"review","venue":"Targeted Oncology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":171,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"Pfizer","keywords":"Bevacizumab; Biosimilar; Medicine; Colorectal cancer; Oncology; Intensive care medicine; Internal medicine; Cancer; Chemotherapy","score_opus":0.060309267353295185,"score_gpt":0.4066597918623675,"score_spread":0.34635052450907233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2742486699","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00058777636,0.9961729,0.0000017237385,0.00039760658,0.0010926209,0.0011523387,0.0002527379,0.000010456668,0.00033183815],"genre_scores_gemma":[0.002019324,0.9973257,0.00006265904,0.000029667402,0.000052969583,0.00031535386,0.000071907474,0.000020866617,0.00010151765],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99623954,0.0018140128,0.0009208226,0.00050573435,0.00003289021,0.00048699035],"domain_scores_gemma":[0.99832743,0.00062732137,0.00065720995,0.0003188004,0.000037596314,0.000031652697],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007954383,0.00043262896,0.0031160163,0.000302792,0.00009957594,0.000009956168,0.00044683972,0.0011349418,0.00022420051],"category_scores_gemma":[0.00015485915,0.00024317385,0.00041016663,0.00018100673,0.0013105513,0.000027411912,0.0002125662,0.0008149238,0.0000112032],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039994117,0.0003169263,0.00008070187,0.00051853096,0.00032970638,0.000017203041,0.000109357876,3.7023938e-7,0.0001441257,0.00018083508,0.00015502541,0.9977473],"study_design_scores_gemma":[0.0046762424,0.00049917906,0.00032037115,0.001152174,0.0009647781,0.00006897802,0.0000390077,0.000009159635,0.0001683835,0.00030581915,0.99154073,0.00025515558],"about_ca_topic_score_codex":0.0005726122,"about_ca_topic_score_gemma":0.0014330497,"teacher_disagreement_score":0.99749213,"about_ca_system_score_codex":0.00041465578,"about_ca_system_score_gemma":0.0006837382,"threshold_uncertainty_score":0.9916342},"labels":[],"label_agreement":null},{"id":"W2743780916","doi":"10.1007/s11523-017-0525-2","title":"A Phase II Multicentre, Open-Label, Proof-of-Concept Study of Tasquinimod in Hepatocellular, Ovarian, Renal Cell, and Gastric Cancers","year":2017,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Sphingolipid Metabolism and Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre; Sunnybrook Health Science Centre","funders":"Ipsen","keywords":"Medicine; Internal medicine; Oncology; Cohort; Clinical endpoint; Cancer; Sorafenib; Nausea; Hepatocellular carcinoma; Response Evaluation Criteria in Solid Tumors; Clinical trial; Gastroenterology; Phases of clinical research","score_opus":0.03434511081770929,"score_gpt":0.32998758412842844,"score_spread":0.29564247331071913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2743780916","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99625224,0.0018527075,0.00024414557,0.00003267999,0.00022607241,0.00097255764,0.000037504145,0.0000036331664,0.0003784578],"genre_scores_gemma":[0.9978653,0.00006615471,0.0016713198,0.00004605933,0.00011443094,0.00006704825,0.00003998907,0.00001964889,0.00011004377],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99846125,0.0001763577,0.00048066155,0.00045027872,0.000116169875,0.0003152609],"domain_scores_gemma":[0.9986946,0.000024210314,0.00053355267,0.00053440145,0.000110718145,0.000102524966],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040814508,0.0001870055,0.0005191876,0.0000946753,0.00017242922,0.000020161786,0.0005908302,0.00019526039,0.000029298779],"category_scores_gemma":[0.00018284917,0.00018154568,0.000030317817,0.00009512423,0.00018606367,0.000015913014,0.0006045652,0.00015226321,2.8814054e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015989545,0.0060375673,0.0057755806,0.000033775086,0.000101946825,0.000040466297,0.002003204,0.00013592649,0.9665951,0.000022714268,0.00024517518,0.017409597],"study_design_scores_gemma":[0.060599957,0.016431272,0.0015551694,0.000037310652,0.00015829167,0.000012158876,0.0013078483,0.0021565056,0.9120677,0.00004372466,0.005268689,0.00036138468],"about_ca_topic_score_codex":0.0013341955,"about_ca_topic_score_gemma":0.00045941846,"teacher_disagreement_score":0.059001002,"about_ca_system_score_codex":0.000031514777,"about_ca_system_score_gemma":0.00035650335,"threshold_uncertainty_score":0.7403218},"labels":[],"label_agreement":null},{"id":"W2765084883","doi":"10.1007/s11523-017-0530-5","title":"A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer","year":2017,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":95,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Plexxikon; Symphogen; Genentech; Celgene; Sanofi; Ipsen; Chugai Pharmaceutical; Sirtex Medical; Pfizer; Eli Lilly and Company","keywords":"Medicine; Irinotecan; Tolerability; Clinical endpoint; Internal medicine; KRAS; Colorectal cancer; Pharmacokinetics; Pharmacology; Phases of clinical research; Combination therapy; Endometrial cancer; Oncology; Cancer; Urology; Toxicity; Adverse effect; Clinical trial","score_opus":0.03309205630219511,"score_gpt":0.3685072594238245,"score_spread":0.3354152031216294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2765084883","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99387354,0.0017747644,0.000030987212,0.0009022313,0.0016702673,0.0014809021,0.0001277361,0.000020483192,0.000119091455],"genre_scores_gemma":[0.99745023,0.000270208,0.0003161992,0.00039808024,0.0005963633,0.0004019366,0.000016783377,0.00006157365,0.0004886522],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99725586,0.0004058643,0.00066801463,0.0007816053,0.0002942851,0.00059434783],"domain_scores_gemma":[0.9974871,0.00012219111,0.00071386923,0.0013342843,0.00020154427,0.00014099135],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005704103,0.00040232838,0.0006114789,0.000088412955,0.00047288902,0.000046992922,0.0010736415,0.0004025481,0.000080228616],"category_scores_gemma":[0.0007000043,0.00023586457,0.00012331625,0.00018161935,0.0006675378,0.00002229534,0.0007544854,0.0005089352,0.0000030942188],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044144318,0.0030706238,0.02407406,0.0000926082,0.00038003596,0.000083677514,0.0038555039,0.0009190509,0.92590743,0.000011569777,0.0033976932,0.03379331],"study_design_scores_gemma":[0.048977233,0.013857043,0.03949884,0.00026900598,0.00037410928,0.00007662195,0.0051401006,0.0014659575,0.7891095,0.000060751885,0.09980402,0.0013667989],"about_ca_topic_score_codex":0.0014945802,"about_ca_topic_score_gemma":0.013780812,"teacher_disagreement_score":0.13679792,"about_ca_system_score_codex":0.00025199345,"about_ca_system_score_gemma":0.000829522,"threshold_uncertainty_score":0.9618278},"labels":[],"label_agreement":null},{"id":"W2789468111","doi":"10.1007/s11523-018-0559-0","title":"Cabozantinib Versus Standard-of-Care Comparators in the Treatment of Advanced/Metastatic Renal Cell Carcinoma in Treatment-naïve Patients: a Systematic Review and Network Meta-Analysis","year":2018,"lang":"en","type":"review","venue":"Targeted Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Ipsen; Canadian Centre for Applied Research in Cancer Control","keywords":"Cabozantinib; Medicine; Sunitinib; Internal medicine; Sorafenib; Oncology; Hazard ratio; Renal cell carcinoma; Meta-analysis; Bevacizumab; Temsirolimus; Progression-free survival; Subgroup analysis; Confidence interval; Overall survival; Hepatocellular carcinoma; Chemotherapy; Discovery and development of mTOR inhibitors","score_opus":0.11091761757752623,"score_gpt":0.38345245457670035,"score_spread":0.27253483699917413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789468111","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00533972,0.9819739,0.000001477434,0.000021946065,0.000102120335,0.011596773,0.00050850527,0.000010534681,0.00044500758],"genre_scores_gemma":[0.013777847,0.9814775,0.00080162135,0.000035061585,0.000034330584,0.0025984175,0.0011602798,0.00005894893,0.000055992143],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9920517,0.0029866192,0.0030280263,0.00083838776,0.0005093332,0.0005858881],"domain_scores_gemma":[0.9939665,0.0018822433,0.0023897707,0.0012670635,0.0003358678,0.00015850973],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0006304622,0.0010301648,0.019900339,0.0007520819,0.00005067696,0.000008653652,0.0002723555,0.00028098997,0.00012183905],"category_scores_gemma":[0.00010195757,0.0005274687,0.0029321662,0.0021378598,0.00024414403,0.000043213124,0.00004319188,0.00022916244,0.000010934637],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021684892,0.0041893786,0.0009010123,0.8429807,0.13397083,0.0007869894,0.0035178394,0.000059846567,1.7582316e-7,0.000024241648,0.00018369839,0.011216793],"study_design_scores_gemma":[0.007827555,0.04039405,0.0001600012,0.01615049,0.902218,0.000028284652,0.0004979063,0.000004226001,0.000009032134,0.0000035406877,0.032332428,0.00037450512],"about_ca_topic_score_codex":0.00019703644,"about_ca_topic_score_gemma":0.00095940416,"teacher_disagreement_score":0.8268302,"about_ca_system_score_codex":0.0019558426,"about_ca_system_score_gemma":0.00078919827,"threshold_uncertainty_score":0.9997177},"labels":[],"label_agreement":null},{"id":"W2900971116","doi":"10.1007/s11523-018-0603-0","title":"Targeting the Proteasome in Refractory Pediatric Leukemia Cells: Characterization of Effective Cytotoxicity of Carfilzomib","year":2018,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Ubiquitin and proteasome pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital; University of Calgary","funders":"Alberta Children's Hospital Foundation","keywords":"Carfilzomib; Medicine; Cytotoxicity; Refractory (planetary science); Cancer research; Proteasome inhibitor; Leukemia; Oncology; Immunology; Multiple myeloma; In vitro; Biochemistry","score_opus":0.00839942384022,"score_gpt":0.2487751456260181,"score_spread":0.2403757217857981,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900971116","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997443,0.00022205136,0.00034600074,0.00002553745,0.00017475993,0.00097628316,0.000044156375,0.000009395314,0.0007588125],"genre_scores_gemma":[0.998625,0.00011334435,0.00029931744,0.00008833554,0.0005355328,0.00014436587,0.00009669676,0.000019051955,0.00007838731],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998492,0.00044827542,0.00039729621,0.00027603304,0.0001115871,0.00027480032],"domain_scores_gemma":[0.9990155,0.00006352796,0.00040933685,0.00025034184,0.00021974898,0.000041547417],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069536775,0.00014624235,0.00027914697,0.00009340866,0.00006090138,0.0000033452848,0.0002356564,0.00029684984,0.0000513274],"category_scores_gemma":[0.00027380136,0.000117185366,0.000068485555,0.0002553256,0.00022241357,0.0000071299164,0.0001366527,0.00018783007,0.000008152476],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030214552,0.00009799603,0.0041734576,0.000071887516,0.000019174004,0.0000021527865,0.00046683685,0.0000098007395,0.9939621,0.00004301946,0.00008583004,0.00076556456],"study_design_scores_gemma":[0.00064750004,0.001510999,0.021974066,0.000008961338,0.000017053462,0.0000024801482,0.000082671955,0.00008002936,0.9726841,0.000048558133,0.0028232462,0.00012034522],"about_ca_topic_score_codex":0.000071385766,"about_ca_topic_score_gemma":0.00002006392,"teacher_disagreement_score":0.021278046,"about_ca_system_score_codex":0.000084710526,"about_ca_system_score_gemma":0.0002957996,"threshold_uncertainty_score":0.47786805},"labels":[],"label_agreement":null},{"id":"W2913025776","doi":"10.1007/s11523-018-00618-0","title":"Randomized, Open-Label, Crossover Studies Evaluating the Effect of Food and Liquid Formulation on the Pharmacokinetics of the Novel Focal Adhesion Kinase (FAK) Inhibitor BI 853520","year":2019,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Cell Adhesion Molecules Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Juravinski Cancer Centre","funders":"Boehringer Ingelheim","keywords":"Medicine; Pharmacokinetics; Focal adhesion; Crossover; Crossover study; Pharmacology; Kinase; Pathology; Phosphorylation; Biochemistry","score_opus":0.08393497142852478,"score_gpt":0.42870015674823336,"score_spread":0.34476518531970857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913025776","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898922,0.0012084956,0.000021031161,0.0025570488,0.00030563094,0.0052559283,0.00001150065,0.000010277828,0.00073791784],"genre_scores_gemma":[0.99864626,0.00012484557,0.00017127737,0.00050884293,0.00009007696,0.00016040659,0.000006010616,0.000026544341,0.00026571564],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9967704,0.0014259686,0.000577712,0.000288141,0.00065800175,0.0002798026],"domain_scores_gemma":[0.9912645,0.007436762,0.0004100059,0.00047767037,0.00035400025,0.000057040117],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040210756,0.0002050777,0.00084143964,0.00008511315,0.0001722105,0.000014375821,0.00034463583,0.00014612105,0.00011040634],"category_scores_gemma":[0.0034291034,0.000084788095,0.00012358848,0.00031694816,0.0005095095,0.000049052687,0.0006669981,0.00046644517,0.000010924921],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16136149,0.00024413098,0.00023798543,0.00020766132,0.000275421,0.0000016858304,0.0005777587,0.000110013905,0.8335797,0.0004865672,0.00045510274,0.0024624444],"study_design_scores_gemma":[0.20479463,0.024940563,0.00049956737,0.00022083391,0.00039060522,0.000012213298,0.00017301166,0.013025424,0.7552974,0.000103916536,0.00044357212,0.00009823853],"about_ca_topic_score_codex":0.000025060239,"about_ca_topic_score_gemma":0.000008408129,"teacher_disagreement_score":0.07828232,"about_ca_system_score_codex":0.00012386375,"about_ca_system_score_gemma":0.00018769543,"threshold_uncertainty_score":0.41052046},"labels":[],"label_agreement":null},{"id":"W2914232272","doi":"10.1007/s11523-018-00617-1","title":"Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies","year":2019,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Cell Adhesion Molecules Research","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Juravinski Cancer Centre","funders":"Boehringer Ingelheim","keywords":"Medicine; Nausea; Proteinuria; Adverse effect; Peripheral edema; Internal medicine; Vomiting; Dosing; Pharmacodynamics; Pharmacokinetics; Gastroenterology; Pharmacology; Oncology; Kidney","score_opus":0.027494360188708336,"score_gpt":0.3522023992081704,"score_spread":0.3247080390194621,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2914232272","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99696285,0.000081341495,0.000020855436,0.000038162456,0.000072719,0.0026548035,0.000015364125,0.000023020892,0.00013089894],"genre_scores_gemma":[0.996335,0.0000079791125,0.0033033446,0.000052032083,0.000007819531,0.00007021134,0.00006452583,0.000029742092,0.00012931337],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99757826,0.0003760615,0.00068213895,0.00041519135,0.0005757116,0.00037262827],"domain_scores_gemma":[0.99840635,0.00028166757,0.00030487968,0.00046938457,0.00038549487,0.00015220836],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032803294,0.00020436087,0.0010448523,0.00047381365,0.000020649035,0.0000024748467,0.0001695846,0.000117149226,0.0004968477],"category_scores_gemma":[0.00029278678,0.00013402547,0.000049137478,0.00069693435,0.00013900858,0.00009809762,0.000102620455,0.00026231437,0.000025139243],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.057976928,0.07480046,0.42720786,0.000948628,0.00018528974,0.0009416326,0.002443044,0.00014503038,0.41744414,0.000038043356,0.00015189353,0.017717047],"study_design_scores_gemma":[0.1348252,0.44915235,0.24238881,0.00039842236,0.0002547417,0.00003506602,0.008755454,0.0009850134,0.16232634,0.00004706735,0.00038821454,0.00044332352],"about_ca_topic_score_codex":0.00006733975,"about_ca_topic_score_gemma":0.00015179341,"teacher_disagreement_score":0.3743519,"about_ca_system_score_codex":0.00013614194,"about_ca_system_score_gemma":0.0003893324,"threshold_uncertainty_score":0.54654},"labels":[],"label_agreement":null},{"id":"W2957412264","doi":"10.1007/s11523-019-00654-4","title":"A Monoclonal Antibody Against β1 Integrin Inhibits Proliferation and Increases Survival in an Orthotopic Model of High-Grade Meningioma","year":2019,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Meningioma and schwannoma management","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Hamilton General Hospital","funders":"Meningioma Mommas","keywords":"Medicine; Integrin; Meningioma; Monoclonal antibody; Cancer research; Protein kinase B; Laminin; In vivo; In vitro; Pathology; Antibody; Cell; Phosphorylation; Immunology; Internal medicine; Biology; Receptor; Cell biology","score_opus":0.027695703254969287,"score_gpt":0.30889896636305775,"score_spread":0.28120326310808846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2957412264","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970092,0.00010352213,0.00026474608,0.0002960821,0.000108474065,0.00083282375,0.000010372607,0.00004291317,0.0013318501],"genre_scores_gemma":[0.99449724,0.0000108490385,0.0048361295,0.00010549244,0.000058857764,0.000038438026,0.00026078694,0.000016965483,0.00017522818],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99850386,0.00018118805,0.00046781864,0.00036372477,0.00021332497,0.00027007656],"domain_scores_gemma":[0.99932915,0.000069385605,0.00015130745,0.000232885,0.000088796136,0.00012844738],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042305456,0.00017662818,0.0005745712,0.00035082974,0.000029325463,0.000010220263,0.000079832644,0.00017443614,0.00004818764],"category_scores_gemma":[0.00006415919,0.00015751032,0.000043429434,0.00021391128,0.000063916734,0.00015301876,0.00008410951,0.00021059677,0.0000069890725],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011941137,0.0010589736,0.47268817,0.00023424371,0.00010221179,0.00037821668,0.0013321212,0.0014997156,0.511194,0.0078959055,0.000041988456,0.0023803562],"study_design_scores_gemma":[0.01665554,0.0071455603,0.5486929,0.00031833336,0.00022007164,0.00023455662,0.0012759938,0.38161963,0.040876176,0.0019869,0.00027343573,0.0007009068],"about_ca_topic_score_codex":0.0002275789,"about_ca_topic_score_gemma":0.00014240251,"teacher_disagreement_score":0.4703178,"about_ca_system_score_codex":0.0000998585,"about_ca_system_score_gemma":0.0001937278,"threshold_uncertainty_score":0.6423085},"labels":[],"label_agreement":null},{"id":"W2962334030","doi":"10.1007/s11523-019-00652-6","title":"Acquired EGFR L718V Mutation as the Mechanism for Osimertinib Resistance in a T790M-Negative Non-Small-Cell Lung Cancer Patient","year":2019,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Power Generation","funders":"","keywords":"Osimertinib; T790M; Medicine; Lung cancer; Oncology; Epidermal growth factor receptor; Adenocarcinoma; Internal medicine; Resistance mutation; Cancer; Cancer research; Gefitinib; Erlotinib; Gene; Biology; Genetics; Polymerase chain reaction","score_opus":0.011041153909476078,"score_gpt":0.32929065762955295,"score_spread":0.3182495037200769,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2962334030","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9705588,0.0011621637,0.00069183484,0.0069001243,0.0008060782,0.005061537,0.00008569136,0.00004878507,0.0146849705],"genre_scores_gemma":[0.9859747,0.000065539905,0.0035899535,0.0032850625,0.000073457144,0.0021479256,0.0001044904,0.000034898072,0.0047239363],"study_design_codex":"qualitative","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987284,0.0000806543,0.00034577277,0.0003522198,0.00014897155,0.00034397244],"domain_scores_gemma":[0.9988894,0.00031630837,0.00022934847,0.00023960382,0.00024727828,0.00007805484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012421164,0.00017716375,0.00034732508,0.000099781755,0.000104575345,0.000009926953,0.0000919244,0.00015380637,0.00031451363],"category_scores_gemma":[0.00008661456,0.00012641618,0.00008854656,0.0002441171,0.000043036063,0.0000642972,0.00002592602,0.00012207753,0.000048457652],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028714271,0.009482682,0.04687369,0.0035306674,0.005708647,0.0010660755,0.450745,0.003300224,0.2826968,0.058563072,0.05412516,0.055193733],"study_design_scores_gemma":[0.14823115,0.024698447,0.102213666,0.002330136,0.0074096676,0.00011118287,0.044168416,0.037432175,0.44590774,0.061244868,0.123247825,0.0030047398],"about_ca_topic_score_codex":0.0007800438,"about_ca_topic_score_gemma":0.0015226854,"teacher_disagreement_score":0.40657657,"about_ca_system_score_codex":0.00093734707,"about_ca_system_score_gemma":0.000866871,"threshold_uncertainty_score":0.5155102},"labels":[],"label_agreement":null},{"id":"W2985618399","doi":"10.1007/s11523-019-00689-7","title":"High Tumor Mutation Burden and Other Immunotherapy Response Predictors in Breast Cancers: Associations and Therapeutic Opportunities","year":2019,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"NOSM University; Essar Steel Algoma (Canada); Sault Area Hospital","funders":"","keywords":"Medicine; Immunotherapy; Oncology; Breast cancer; Internal medicine; Mutation; Immunology; Cancer; Genetics; Gene","score_opus":0.022687232918031704,"score_gpt":0.2912074542816495,"score_spread":0.2685202213636178,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2985618399","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891472,0.0035820098,0.000005542009,0.0059552114,0.00023531665,0.0005594228,0.00009656068,0.000048814985,0.00036994976],"genre_scores_gemma":[0.99530524,0.0005394347,0.00013390034,0.0029986654,0.00009751995,0.000055237873,0.000030546962,0.000029562605,0.00080988166],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9988394,0.0002618575,0.0003034664,0.00022917065,0.00013204907,0.00023407167],"domain_scores_gemma":[0.9993098,0.00027081772,0.000153681,0.00014990356,0.00005450607,0.000061306244],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057580223,0.00014922486,0.00035531752,0.00022005975,0.00005460921,0.000016097722,0.00004889587,0.00014738849,0.0005886182],"category_scores_gemma":[0.000019493607,0.00013232882,0.00003995223,0.0001608139,0.00015696642,0.00006717394,0.000014067923,0.00016775406,0.000005467014],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.073299155,0.00031029913,0.32311845,0.00013322182,0.0015716475,0.00023034263,0.02330229,0.000056671845,0.35257465,0.0007511871,0.00096979615,0.22368228],"study_design_scores_gemma":[0.012695258,0.0022086066,0.91335696,0.00009804192,0.00007947833,0.00040035538,0.0042611444,0.00034761164,0.0006262399,0.0003006734,0.06535532,0.0002703245],"about_ca_topic_score_codex":0.0027575644,"about_ca_topic_score_gemma":0.0001766306,"teacher_disagreement_score":0.5902385,"about_ca_system_score_codex":0.0006022614,"about_ca_system_score_gemma":0.00052740757,"threshold_uncertainty_score":0.64449567},"labels":[],"label_agreement":null},{"id":"W2989651221","doi":"10.1007/s11523-019-00685-x","title":"Adjusting Overall Survival Estimates for Treatment Switching in Metastatic, Castration-Sensitive Prostate Cancer: Results from the LATITUDE Study","year":2019,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Castration; Internal medicine; Prostate; Cancer; Hormone","score_opus":0.06205601479162649,"score_gpt":0.388488184776486,"score_spread":0.3264321699848595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2989651221","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905395,0.0006829297,0.000043246127,0.002779356,0.00032559814,0.004759546,0.00040959986,0.000041440446,0.0004187845],"genre_scores_gemma":[0.9956095,0.00015317292,0.00229343,0.00012394124,0.00014309854,0.0005167823,0.0005222168,0.000027430877,0.0006104147],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99826306,0.00020465253,0.00042991567,0.0004489498,0.00021657205,0.00043685842],"domain_scores_gemma":[0.9973498,0.002000702,0.00016288337,0.00024442386,0.00015858436,0.000083626546],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050159235,0.00021798909,0.0006052415,0.000079164056,0.00012664574,0.000025567591,0.00007653965,0.00006285586,0.000046137],"category_scores_gemma":[0.00022203592,0.00013135013,0.0000717116,0.0001535101,0.000040980856,0.00008615873,0.000038983333,0.0001719741,0.00001842058],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031326227,0.003513669,0.8071624,0.00009367232,0.002830668,0.0009144856,0.067793496,0.005845375,0.03299592,0.00021774501,0.00036919778,0.046937115],"study_design_scores_gemma":[0.09006305,0.014641116,0.835722,0.00026145225,0.0011651806,0.000018380826,0.022674683,0.023348277,0.009048719,0.0008717361,0.0017129957,0.00047236995],"about_ca_topic_score_codex":0.014506008,"about_ca_topic_score_gemma":0.012858659,"teacher_disagreement_score":0.05873682,"about_ca_system_score_codex":0.00085259095,"about_ca_system_score_gemma":0.0007449758,"threshold_uncertainty_score":0.9920565},"labels":[],"label_agreement":null},{"id":"W3092483376","doi":"10.1007/s11523-020-00748-4","title":"Efficacy and Safety of ABP 798: Results from the JASMINE Trial in Patients with Follicular Lymphoma in Comparison with Rituximab Reference Product","year":2020,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Amgen","keywords":"Medicine; Rituximab; Internal medicine; Follicular lymphoma; Clinical endpoint; Confidence interval; CD20; Randomized controlled trial; Lymphoma; Gastroenterology; Ofatumumab; Oncology","score_opus":0.030366827538506908,"score_gpt":0.2829847304425309,"score_spread":0.252617902904024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3092483376","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99397635,0.0008601223,0.000037239086,0.0035704025,0.000090727655,0.0010171299,0.00014292379,0.000015628977,0.00028946775],"genre_scores_gemma":[0.9974738,0.000030707415,0.001803433,0.0004311252,0.000027957602,0.000016029046,0.00019142043,0.000009799661,0.000015763562],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99780667,0.00077270204,0.0006003626,0.00047618287,0.000058230355,0.00028583582],"domain_scores_gemma":[0.99862045,0.0007723157,0.00025005187,0.00025145107,0.000071421186,0.0000343104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042860562,0.0001877664,0.00075375516,0.000048658498,0.000048368864,0.000004591113,0.00021664712,0.00026876054,0.000056649995],"category_scores_gemma":[0.0004973854,0.000103487495,0.000025763396,0.00035277766,0.00043888995,0.000034800807,0.00009050237,0.00030187317,0.0000062889544],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8510591,0.00411478,0.09266313,0.000022679516,0.00041590576,0.000026483422,0.0021457383,0.000026050815,0.0057758065,0.00020295639,0.0012970262,0.04225034],"study_design_scores_gemma":[0.30204,0.008689594,0.66052413,0.00006969572,0.00013232413,0.0000023737575,0.00018712382,0.000040291034,0.0051865564,0.000038895694,0.022846965,0.0002420307],"about_ca_topic_score_codex":0.00038764172,"about_ca_topic_score_gemma":0.0004933921,"teacher_disagreement_score":0.567861,"about_ca_system_score_codex":0.00004937149,"about_ca_system_score_gemma":0.00012348067,"threshold_uncertainty_score":0.42200974},"labels":[],"label_agreement":null},{"id":"W3095962378","doi":"10.1007/s11523-020-00770-6","title":"Everolimus in Advanced Breast Cancer: A Systematic Review and Meta-analysis","year":2020,"lang":"en","type":"review","venue":"Targeted Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; Western University","funders":"","keywords":"Medicine; Everolimus; Exemestane; Oncology; Internal medicine; Hazard ratio; Breast cancer; Odds ratio; Metastatic breast cancer; Meta-analysis; Confidence interval; Cancer; Aromatase","score_opus":0.06320616612665578,"score_gpt":0.4072449643067012,"score_spread":0.34403879818004546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095962378","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[1.7305048e-7,0.9902333,0.00003752101,0.0031635582,0.00006206219,0.0057341517,0.00056728837,0.00010092753,0.00010101706],"genre_scores_gemma":[0.00000979028,0.9894756,0.0008036016,0.0039913477,0.000066331144,0.0050462843,0.00015329572,0.00010566819,0.00034807378],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99528265,0.00092617463,0.0019107424,0.0010196128,0.00031769375,0.0005431447],"domain_scores_gemma":[0.99690664,0.00043365223,0.0013584365,0.0007986491,0.00017049446,0.000332102],"candidate_categories":["metaepi_narrow","metaepi_broad","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004822548,0.00086993625,0.026421996,0.0006029755,0.00004179889,0.000009506435,0.00030947212,0.00045775354,0.0013317664],"category_scores_gemma":[0.0001931611,0.0005859674,0.002451215,0.0025299636,0.00013603889,0.000093819544,0.0001345892,0.00091837696,0.00006076755],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000046335652,0.000066282024,0.0000014784918,0.753356,0.16576034,0.00027475326,0.000055215507,0.000002554681,2.9106207e-7,0.000015500553,0.00003729704,0.080383964],"study_design_scores_gemma":[0.00047655706,0.0001154536,0.0000044282588,0.031006427,0.68319976,0.00081244344,0.000015328586,0.0000034638267,5.9509077e-8,0.000013305743,0.28403267,0.0003200739],"about_ca_topic_score_codex":0.00008153608,"about_ca_topic_score_gemma":0.00015853756,"teacher_disagreement_score":0.7223496,"about_ca_system_score_codex":0.0011751541,"about_ca_system_score_gemma":0.0009924308,"threshold_uncertainty_score":0.9996592},"labels":[],"label_agreement":null},{"id":"W3111069302","doi":"10.1007/s11523-020-00778-y","title":"Real-World Healthcare Resource Utilization in Patients with Classical Hodgkin Lymphoma Treated with Pembrolizumab and Nivolumab in the USA","year":2020,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Merck Sharp and Dohme","keywords":"Medicine; Pembrolizumab; Nivolumab; Internal medicine; Population; Cohort; Retrospective cohort study; Oncology; Cancer; Immunotherapy; Environmental health","score_opus":0.03138123723126232,"score_gpt":0.29211950405521697,"score_spread":0.2607382668239546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3111069302","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98647094,0.000116212315,0.0000025717545,0.010355495,0.000010691692,0.0009708356,0.000013741266,0.000034634086,0.0020248934],"genre_scores_gemma":[0.9967493,0.000056156543,0.00018657955,0.0025354263,0.000039998187,0.00012505014,0.0002359443,0.000023761124,0.00004780125],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983649,0.0003163219,0.0002926987,0.00041034873,0.00025695132,0.00035874313],"domain_scores_gemma":[0.9992856,0.00015953454,0.000110376546,0.00020199547,0.000064519896,0.00017801287],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010182003,0.0002063803,0.00048007557,0.00015065452,0.0000631076,0.000012810629,0.00007636839,0.00013297806,0.00003263498],"category_scores_gemma":[0.00003827471,0.00011960294,0.000024589626,0.00073677534,0.00012756554,0.00005125324,0.000027714714,0.00014069125,0.000008106094],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061295293,0.001181097,0.9732995,0.00003753287,0.000039819053,0.00041238978,0.0012976245,0.000008855739,0.000004693057,0.00025857202,0.00051826396,0.01681209],"study_design_scores_gemma":[0.025854938,0.007923138,0.95961165,0.00007524346,0.00007719097,0.00002449942,0.00025611592,0.00029470155,0.00004932332,0.0000078602825,0.0057051415,0.00012019196],"about_ca_topic_score_codex":0.0023100341,"about_ca_topic_score_gemma":0.015000879,"teacher_disagreement_score":0.019725408,"about_ca_system_score_codex":0.0006896252,"about_ca_system_score_gemma":0.00033347978,"threshold_uncertainty_score":0.83708423},"labels":[],"label_agreement":null},{"id":"W3157804315","doi":"10.1007/s11523-021-00813-6","title":"Multicenter, Open-Label, Phase I Study of DSP-7888 Dosing Emulsion in Patients with Advanced Malignancies","year":2021,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Renal and related cancers","field":"Biochemistry, Genetics and Molecular Biology","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Sumitomo Dainippon Pharma Oncology","keywords":"Medicine; Tolerability; Adverse effect; Discontinuation; Internal medicine; Phases of clinical research; Cancer; Dosing; Oncology; Clinical trial","score_opus":0.012801173832122325,"score_gpt":0.31028738123255467,"score_spread":0.29748620740043236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3157804315","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981756,0.00066249486,0.000033849232,0.000043551845,0.00020119594,0.0004948695,0.000013670655,0.0000053301733,0.00036938748],"genre_scores_gemma":[0.99848145,0.00011848648,0.00089297886,0.00014021638,0.000019626033,0.000033574182,0.0001571792,0.000016717358,0.00013974572],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99885845,0.00015065199,0.00029381635,0.00035628493,0.00011143179,0.00022937686],"domain_scores_gemma":[0.9993517,0.000013339436,0.00016043277,0.0002330735,0.00018504495,0.000056422832],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007310595,0.00013825388,0.0002840142,0.000047195823,0.000050011604,0.000008785105,0.00018719705,0.00014997952,0.000022547414],"category_scores_gemma":[0.00004460802,0.00011019986,0.000019884817,0.0001976219,0.000059377842,0.000008972369,0.0001932789,0.00012440636,0.000001931405],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0053728106,0.011125129,0.031839725,0.000031350028,0.0001758162,0.00009160088,0.00059269514,0.00060569297,0.9249942,0.0000056469416,0.00020346689,0.02496189],"study_design_scores_gemma":[0.14980558,0.038918864,0.046800297,0.00023542895,0.00014614123,0.000011922702,0.0030516598,0.00016632247,0.7501227,0.000023958859,0.010046434,0.00067066407],"about_ca_topic_score_codex":0.00005278395,"about_ca_topic_score_gemma":0.00019346982,"teacher_disagreement_score":0.17487144,"about_ca_system_score_codex":0.00005452123,"about_ca_system_score_gemma":0.0001266255,"threshold_uncertainty_score":0.44938198},"labels":[],"label_agreement":null},{"id":"W3172387625","doi":"10.1007/s11523-021-00822-5","title":"Risk and Benefit for Targeted Therapy Agents in Pediatric Phase II Trials in Oncology: A Systematic Review with a Meta-Analysis","year":2021,"lang":"en","type":"review","venue":"Targeted Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Narodowe Centrum Nauki","keywords":"Medicine; Meta-analysis; Oncology; Targeted therapy; Clinical trial; Internal medicine; Pediatric oncology; Intensive care medicine; Cancer","score_opus":0.7192358579784843,"score_gpt":0.652057374042999,"score_spread":0.06717848393548531,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172387625","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000078317295,0.976823,0.00007499807,0.001335987,0.00011880712,0.020941405,0.00047051505,0.000038152913,0.00011886646],"genre_scores_gemma":[0.00003162779,0.97993004,0.003337583,0.0014659768,0.00018213986,0.013082083,0.0009807365,0.00012510642,0.0008646896],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.97579646,0.012425097,0.007847525,0.0018157759,0.0011179395,0.0009971767],"domain_scores_gemma":[0.8752439,0.11564281,0.00552165,0.0018123975,0.0012036038,0.0005756214],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.06966418,0.0010004436,0.045075558,0.0024860327,0.00013598538,0.000030167417,0.00066785293,0.00286666,0.0010686314],"category_scores_gemma":[0.108230196,0.0005934852,0.005638743,0.0056771203,0.0002475843,0.000064656844,0.00030419038,0.0049313405,0.00001654461],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006458588,0.0036616155,0.000056936347,0.80907476,0.13682912,0.0009767603,0.00022434095,0.000002925738,2.1127128e-7,0.00019624135,0.00045010285,0.047881145],"study_design_scores_gemma":[0.009814103,0.009024778,0.000008443047,0.049893714,0.80391455,0.00008210688,0.000047383262,0.000032052565,4.1179345e-7,0.00066112954,0.125954,0.0005673115],"about_ca_topic_score_codex":0.00015446384,"about_ca_topic_score_gemma":0.0019886082,"teacher_disagreement_score":0.759181,"about_ca_system_score_codex":0.0012321139,"about_ca_system_score_gemma":0.005586476,"threshold_uncertainty_score":0.99984455},"labels":[],"label_agreement":null},{"id":"W4238104384","doi":"10.1007/s11523-020-00772-4","title":"Correction to: Efficacy and Safety of ABP 798: Results from the JASMINE Trial in Patients with Follicular Lymphoma in Comparison with Rituximab Reference Product","year":2020,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Paragraph; Rituximab; Follicular lymphoma; Lymphoma; Internal medicine; Medical physics; Oncology; World Wide Web","score_opus":0.022459294506606785,"score_gpt":0.2756866625027647,"score_spread":0.2532273679961579,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4238104384","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940767,0.00017673231,0.000008038482,0.0030476456,0.00014433522,0.0021583133,0.000047800182,0.000017503602,0.00032288025],"genre_scores_gemma":[0.99855304,0.000021577847,0.00060970016,0.00036424366,0.000069240785,0.00008569688,0.00027554223,0.000011795365,0.000009141576],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985637,0.0001646543,0.00046243976,0.0004167795,0.00020584624,0.00018656731],"domain_scores_gemma":[0.99894917,0.00044957642,0.00018658585,0.00022586512,0.000087920795,0.00010088613],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015142222,0.00016040815,0.00063631526,0.000057918984,0.000031903997,0.000005220001,0.00006859991,0.00007141687,0.000011907995],"category_scores_gemma":[0.000424709,0.00009109738,0.000019673083,0.00038807862,0.00007146352,0.000034012224,0.000037933747,0.000096142925,0.000006045025],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4457036,0.005711347,0.50992745,0.000012072032,0.0001362133,0.000060687067,0.0028812082,0.00014152183,0.00008669858,0.000009677274,0.0018216063,0.033507902],"study_design_scores_gemma":[0.24655788,0.010783771,0.7387747,0.00012479571,0.00009699731,0.0000021588114,0.00012713255,0.00014892411,0.0006846313,0.0000015344955,0.0026182646,0.000079190904],"about_ca_topic_score_codex":0.002205532,"about_ca_topic_score_gemma":0.0017749587,"teacher_disagreement_score":0.22884725,"about_ca_system_score_codex":0.0002639568,"about_ca_system_score_gemma":0.00022786549,"threshold_uncertainty_score":0.37148434},"labels":[],"label_agreement":null},{"id":"W4281722441","doi":"10.1007/s11523-022-00884-z","title":"A Phase 2 Trial of Afatinib in Patients with Solid Tumors that Harbor Genomic Aberrations in the HER family: The MOBILITY3 Basket Study","year":2022,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Boehringer Ingelheim","keywords":"Medicine; Afatinib; Internal medicine; Oncology; Response Evaluation Criteria in Solid Tumors; Neratinib; Cancer; Epidermal growth factor receptor; Breast cancer; Clinical trial; Erlotinib; Phases of clinical research; Trastuzumab","score_opus":0.06037269198487216,"score_gpt":0.3976504848924063,"score_spread":0.3372777929075341,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281722441","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906309,0.00007477202,0.000003218423,0.0016511341,0.00019860028,0.0063306736,0.00006467061,0.000013501083,0.0010325073],"genre_scores_gemma":[0.9966329,0.0000040278837,0.000051359795,0.0006831027,0.00006991305,0.0024320998,0.000038543272,0.00002430003,0.000063750354],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99617904,0.0018996149,0.0005330911,0.00032485378,0.00068455364,0.00037882314],"domain_scores_gemma":[0.9985084,0.00055676745,0.00017356996,0.0006203688,0.00008485038,0.00005604618],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025104578,0.00014350632,0.0004946864,0.00022288856,0.00013729121,0.0000082435145,0.0004163508,0.00005549452,0.0006613979],"category_scores_gemma":[0.0002563814,0.00008481225,0.000053988842,0.0007316454,0.00020816714,0.00003737838,0.0001551904,0.00087557203,0.000006332511],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19881319,0.08735282,0.6199746,0.000087227265,0.00035738945,0.00042434444,0.07346888,0.0010145821,0.0024228997,0.0000929484,0.008171339,0.007819805],"study_design_scores_gemma":[0.20789321,0.05190501,0.7054503,0.000017719438,0.000087709355,0.000004907346,0.02772318,0.00050949486,0.000072777424,0.00006678484,0.0061079375,0.00016095542],"about_ca_topic_score_codex":0.0008565953,"about_ca_topic_score_gemma":0.0010228639,"teacher_disagreement_score":0.08547573,"about_ca_system_score_codex":0.0006614012,"about_ca_system_score_gemma":0.0012227546,"threshold_uncertainty_score":0.7241843},"labels":[],"label_agreement":null},{"id":"W4283026383","doi":"10.1007/s11523-022-00888-9","title":"Cobimetinib in Pediatric and Young Adult Patients with Relapsed or Refractory Solid Tumors (iMATRIX-cobi): A Multicenter, Phase I/II Study","year":2022,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"National Cancer Institute; Genentech; F. Hoffmann-La Roche","keywords":"Medicine; Refractory (planetary science); Multicenter study; Phases of clinical research; Internal medicine; Oncology; Clinical trial; Randomized controlled trial","score_opus":0.008484783094617332,"score_gpt":0.27110953133376103,"score_spread":0.2626247482391437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283026383","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99775237,0.00024334222,0.0000122252195,0.00003180919,0.000389837,0.0010783643,0.000108437765,0.000025563815,0.00035805805],"genre_scores_gemma":[0.9981713,0.000056784775,0.00033573745,0.00021669397,0.000119367294,0.0003037534,0.00039205275,0.000039831197,0.000364428],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9979176,0.00041372722,0.00044034747,0.000595669,0.00021038693,0.00042227333],"domain_scores_gemma":[0.99914473,0.000038719456,0.00025774885,0.00031638608,0.00010972588,0.00013270695],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030413043,0.00024668433,0.0003832438,0.00018022559,0.00025583926,0.000009195833,0.00022301353,0.0001282495,0.00011678686],"category_scores_gemma":[0.00016642216,0.00020925846,0.000042317184,0.000253646,0.00006013284,0.000007883665,0.00040001023,0.00033502944,0.000004257279],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033551306,0.026477167,0.86671895,0.00009512214,0.00021628378,0.0009448751,0.00394666,0.00005321165,0.055481773,0.000017760269,0.0055099917,0.006986885],"study_design_scores_gemma":[0.1872081,0.41630644,0.33352226,0.000026745349,0.00057692366,0.00022688929,0.011497902,0.00061301177,0.0076054484,0.000025331046,0.04003537,0.0023555642],"about_ca_topic_score_codex":0.00010113702,"about_ca_topic_score_gemma":0.0005519096,"teacher_disagreement_score":0.5331967,"about_ca_system_score_codex":0.000090858375,"about_ca_system_score_gemma":0.0002767717,"threshold_uncertainty_score":0.85333127},"labels":[],"label_agreement":null},{"id":"W4301600257","doi":"10.1007/s11523-022-00920-y","title":"Do Early Phase Oncology Trials Predict Clinical Efficacy in Subsequent Biomarker-Enriched Phase III Randomized Trials?","year":2022,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; University Health Network; University of Toronto; Canadian Centre for Applied Research in Cancer Control; Sunnybrook Hospital","funders":"","keywords":"Medicine; Randomized controlled trial; Clinical endpoint; Clinical trial; Internal medicine; Confidence interval; Biomarker; Surrogate endpoint; Phases of clinical research; Oncology","score_opus":0.7138172971596959,"score_gpt":0.6583019463492661,"score_spread":0.0555153508104298,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4301600257","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"methods","model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7979239,0.0017160987,0.13681535,0.0053460887,0.022489922,0.026270224,0.0018176845,0.0009110622,0.0067096464],"genre_scores_gemma":[0.6089014,0.00059559854,0.38054144,0.0015987752,0.0024915314,0.00506606,0.0001799728,0.00024178751,0.00038344171],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.69062465,0.27943224,0.024142286,0.002319152,0.0015844451,0.0018972415],"domain_scores_gemma":[0.26853192,0.7212972,0.0075009963,0.0014727048,0.0003475185,0.0008496629],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.34753045,0.0008539583,0.0192384,0.000851528,0.00035372822,0.00006998505,0.0014264197,0.0014635035,0.015455894],"category_scores_gemma":[0.7929523,0.00069326395,0.0030946853,0.0014469849,0.0014868496,0.00012353215,0.00084651285,0.0030899118,0.000085846936],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6523542,0.032410882,0.00003855601,0.00005757272,0.0023671642,0.0013007799,0.00088236795,0.000016268643,0.003575805,0.034486793,0.02069665,0.25181296],"study_design_scores_gemma":[0.62963325,0.00883469,0.000046394012,0.000025036965,0.0020574513,0.000041057916,0.0002188465,0.0012669559,0.00018659087,0.33972114,0.017436888,0.0005316752],"about_ca_topic_score_codex":0.000109384986,"about_ca_topic_score_gemma":0.000017254746,"teacher_disagreement_score":0.44542184,"about_ca_system_score_codex":0.0014515669,"about_ca_system_score_gemma":0.0020932122,"threshold_uncertainty_score":0.9998328},"labels":[],"label_agreement":null},{"id":"W4310595717","doi":"10.1007/s11523-022-00931-9","title":"Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid Tumors","year":2022,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"Mirati Therapeutics","keywords":"Medicine; Nausea; Pharmacokinetics; Vomiting; Adverse effect; Internal medicine; Gastroenterology; Cancer; Response Evaluation Criteria in Solid Tumors; Capsule; Pharmacology; Chemotherapy; Progressive disease","score_opus":0.017397823526277143,"score_gpt":0.3924252135381065,"score_spread":0.37502739001182933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310595717","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99715614,0.00041705885,0.000007213415,0.000046509762,0.000087504384,0.0018682799,0.00010824081,0.000014711096,0.00029433818],"genre_scores_gemma":[0.9970857,0.000004298767,0.0019697435,0.00021433894,0.00002744507,0.0005475041,0.00005633682,0.000028256025,0.000066392604],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988573,0.0001369488,0.00030510843,0.00031132606,0.00018754613,0.00020177991],"domain_scores_gemma":[0.99940795,0.000056887544,0.0002087801,0.0001429384,0.00008762399,0.000095794625],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020872496,0.00014200558,0.00042467206,0.00014163369,0.000105648964,0.00000405135,0.000042726075,0.000032452754,0.00013527705],"category_scores_gemma":[0.000018752035,0.00011564093,0.000015284622,0.00019577496,0.000052232925,0.000057818746,0.00007340485,0.00015918809,1.8117515e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002602349,0.007667087,0.93456644,0.000089938345,0.0001890496,0.00003906879,0.019748015,0.0005206783,0.005130203,0.0000037416096,0.00003405384,0.029409386],"study_design_scores_gemma":[0.19241057,0.1402149,0.6292018,0.0001603555,0.0017771857,0.000013234905,0.028172385,0.004297727,0.0027591405,0.00003471213,0.00045502218,0.00050289894],"about_ca_topic_score_codex":0.00054882787,"about_ca_topic_score_gemma":0.00037069982,"teacher_disagreement_score":0.30536458,"about_ca_system_score_codex":0.00028241973,"about_ca_system_score_gemma":0.00040338846,"threshold_uncertainty_score":0.47157001},"labels":[],"label_agreement":null},{"id":"W4317209129","doi":"10.1007/s11523-022-00941-7","title":"Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies","year":2023,"lang":"en","type":"review","venue":"Targeted Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"AstraZeneca","keywords":"Medicine; Osimertinib; Lung cancer; Central nervous system; Lung; Oncology; Pathology; Cancer; Cancer research; Internal medicine; Adenocarcinoma","score_opus":0.0675653515167773,"score_gpt":0.43998593053210705,"score_spread":0.37242057901532977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317209129","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011626704,0.99070674,0.00017230476,0.00036645163,0.0019403342,0.005584418,0.000696,0.00016500284,0.0002524772],"genre_scores_gemma":[0.0010037448,0.9932168,0.00022579155,0.00006390811,0.0015086563,0.0033486101,0.0003128446,0.00011981959,0.00019980811],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99741375,0.00023730946,0.00065079756,0.00083994376,0.00020717204,0.0006510506],"domain_scores_gemma":[0.9981022,0.000579492,0.00051615725,0.00036419358,0.000200798,0.0002371757],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002055384,0.0006255333,0.0021246856,0.00025892176,0.00020579892,0.000054089607,0.0001722579,0.0003553014,0.000053624888],"category_scores_gemma":[0.000025211692,0.00042086997,0.0004663678,0.00036097917,0.00009817953,0.00008279788,0.000045063043,0.00051069155,0.000015486521],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027322373,0.0005525644,0.000022348859,0.081511445,0.003996351,0.0001729783,0.0048768395,0.000021728172,0.000013089466,0.002180678,0.001291752,0.905087],"study_design_scores_gemma":[0.0022015416,0.0019854414,0.00011263003,0.02219195,0.026445016,0.00009203528,0.014817723,0.00021184079,0.000007174259,0.000017814102,0.9313752,0.00054162194],"about_ca_topic_score_codex":0.0001803535,"about_ca_topic_score_gemma":0.000072461466,"teacher_disagreement_score":0.93008345,"about_ca_system_score_codex":0.0022830046,"about_ca_system_score_gemma":0.004120292,"threshold_uncertainty_score":0.9998243},"labels":[],"label_agreement":null},{"id":"W4319460408","doi":"10.1007/s11523-023-00947-9","title":"Correction to: Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies","year":2023,"lang":"en","type":"erratum","venue":"Targeted Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Osimertinib; Lung cancer; Central nervous system; Lung; Oncology; Mutant; Cancer; Cancer research; Neuroscience; Internal medicine; Epidermal growth factor receptor; Erlotinib; Biology; Gene","score_opus":0.026562778920250763,"score_gpt":0.37817529279251416,"score_spread":0.3516125138722634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319460408","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012273633,0.537187,0.004022492,0.011482408,0.39627492,0.021924715,0.0030229578,0.0012803426,0.012531544],"genre_scores_gemma":[0.61970097,0.1508675,0.0020783674,0.0027711333,0.057306632,0.023855463,0.006530271,0.001290509,0.13559915],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99753165,0.00015047453,0.0004643577,0.00090662134,0.00027140902,0.0006755023],"domain_scores_gemma":[0.9982737,0.00036818287,0.00035862532,0.00033762676,0.00037526453,0.00028662937],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001736527,0.0005435926,0.0010010058,0.00032041632,0.00027110815,0.00007038152,0.00014382905,0.0003979332,0.00006476051],"category_scores_gemma":[0.000056063483,0.00042323399,0.00023136534,0.00037378178,0.000073294716,0.00009210152,0.00004339095,0.0008041242,0.000015215674],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020778836,0.00088180247,0.00027154834,0.005109618,0.002800504,0.00017278233,0.02083995,0.00049240934,0.0007919188,0.0005805481,0.9035972,0.06238388],"study_design_scores_gemma":[0.0062486096,0.01052486,0.011598554,0.007958312,0.01535363,0.00012162727,0.10751449,0.008267138,0.0004027641,0.000037064223,0.8306818,0.0012911252],"about_ca_topic_score_codex":0.0008037427,"about_ca_topic_score_gemma":0.0007309281,"teacher_disagreement_score":0.6074273,"about_ca_system_score_codex":0.0030081512,"about_ca_system_score_gemma":0.0036881315,"threshold_uncertainty_score":0.99982196},"labels":[],"label_agreement":null},{"id":"W4366351020","doi":"10.1007/s11523-023-00957-7","title":"Place in Therapy of Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: A Targeted Literature Review","year":2023,"lang":"en","type":"review","venue":"Targeted Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"Pfizer","keywords":"Medicine; Oncology; Metastatic breast cancer; Breast cancer; Internal medicine; Palbociclib; Targeted therapy; Chemotherapy; Cyclin-dependent kinase 4; Cancer; Clinical trial; Cell cycle; Cyclin-dependent kinase 2","score_opus":0.03738858245496208,"score_gpt":0.39182272420085024,"score_spread":0.35443414174588816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366351020","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011200283,0.9918593,0.0000015632882,0.0018384861,0.00086483045,0.0042597335,0.0007966116,0.00015060016,0.00011685925],"genre_scores_gemma":[0.000041744268,0.99503857,0.0002384123,0.0009730776,0.0005224151,0.0018581563,0.0006970182,0.00024599777,0.00038461125],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9940795,0.00095016416,0.0024411222,0.0010974089,0.0005239445,0.0009078669],"domain_scores_gemma":[0.9967598,0.00051243586,0.0013481968,0.00086005457,0.00027404842,0.00024547655],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0010064911,0.0009881755,0.006519103,0.0013705028,0.000032549877,0.000009233269,0.0004903257,0.0012509655,0.00043305042],"category_scores_gemma":[0.00018757075,0.0007876815,0.00069641566,0.0036897622,0.00021452141,0.00012863848,0.00015814883,0.0023144416,0.000059610833],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00068930216,0.00053455896,0.0001656713,0.066716775,0.0003871562,0.001690596,0.0003693348,0.000010495549,0.00007091243,0.00001712544,0.0010892336,0.92825884],"study_design_scores_gemma":[0.003495185,0.0003348967,0.00023252745,0.2431091,0.00030894656,0.00062428054,0.000043199634,0.0000031600723,0.000016203276,0.00006594577,0.7512399,0.0005266579],"about_ca_topic_score_codex":0.00038843002,"about_ca_topic_score_gemma":0.0005301843,"teacher_disagreement_score":0.92773217,"about_ca_system_score_codex":0.0023482323,"about_ca_system_score_gemma":0.002833559,"threshold_uncertainty_score":0.99998724},"labels":[],"label_agreement":null},{"id":"W4379509021","doi":"10.1007/s11523-023-00965-7","title":"A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors","year":2023,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Insect Resistance and Genetics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Alberta","funders":"AstraZeneca","keywords":"Medicine; Tolerability; Oncology; Internal medicine; Pharmacology; Adverse effect","score_opus":0.007141951924465786,"score_gpt":0.3043287191005847,"score_spread":0.2971867671761189,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379509021","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979107,0.00017283874,0.0000059118856,0.0005769197,0.000129684,0.0010344973,0.0000106651,0.00000955532,0.00014927465],"genre_scores_gemma":[0.9994047,0.000042377338,0.00005294228,0.00030038794,0.000044269273,0.00005785364,0.000025609852,0.000022866103,0.000048972714],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998477,0.00023988038,0.00042305677,0.00036809838,0.0001706375,0.00032132],"domain_scores_gemma":[0.9991884,0.000096867094,0.00017834613,0.00041526835,0.000083840554,0.000037267786],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003452564,0.00018189213,0.00032606267,0.00006770404,0.00012250361,0.000013195987,0.000249017,0.00013332575,0.000007317822],"category_scores_gemma":[0.00011300484,0.00011434113,0.00004764421,0.00040063943,0.00019054707,0.00000692736,0.0001507061,0.00019194034,0.000001528695],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007936421,0.0065777334,0.8490409,0.000059845053,0.00015052798,0.00003304987,0.0042031785,0.0033201543,0.104092255,0.000018447776,0.0002853156,0.024282169],"study_design_scores_gemma":[0.015769698,0.006249114,0.9467859,0.000046087367,0.000021141273,0.0000018608781,0.0009924195,0.0001302508,0.02639379,0.00008093577,0.003321067,0.00020771897],"about_ca_topic_score_codex":0.000061353145,"about_ca_topic_score_gemma":0.0023673296,"teacher_disagreement_score":0.097745016,"about_ca_system_score_codex":0.00006290409,"about_ca_system_score_gemma":0.00022084439,"threshold_uncertainty_score":0.4662696},"labels":[],"label_agreement":null},{"id":"W4386346584","doi":"10.1007/s11523-023-00995-1","title":"Comparative Effectiveness of Lurbinectedin for the Treatment of Relapsed Small Cell Lung Cancer in the Post-Platinum Setting: A Real-World Canadian Synthetic Control Arm Analysis","year":2023,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; CancerCare Manitoba; University of Calgary","funders":"Jazz Pharmaceuticals Canada","keywords":"Medicine; Hazard ratio; Confidence interval; Proportional hazards model; Population; Internal medicine; Oncology; Chemotherapy; Surgery; Environmental health","score_opus":0.027790270941448557,"score_gpt":0.3760701408180536,"score_spread":0.3482798698766051,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386346584","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9831791,0.0023760856,0.00003676093,0.00611405,0.00016080392,0.0053638876,0.00070553354,0.000029823974,0.0020339866],"genre_scores_gemma":[0.99703056,0.00032685915,0.00004617685,0.00009604316,0.00005442079,0.0020665482,0.00009442216,0.000015834616,0.00026915653],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979017,0.0007349748,0.00038602905,0.00028375574,0.00020474847,0.00048883713],"domain_scores_gemma":[0.990859,0.0081276335,0.00020101776,0.00032734536,0.00039154856,0.00009347211],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010994952,0.00018637859,0.0010707455,0.0006916682,0.00012210906,0.0000043421023,0.00018213643,0.000085022075,0.000065893255],"category_scores_gemma":[0.00025836533,0.000103229344,0.00023981881,0.0019378819,0.00022361978,0.000014203105,0.000016462536,0.0001737029,0.0000018644625],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014057249,0.0022651076,0.81991184,0.0018694088,0.022324566,0.00029334423,0.06476423,0.025309378,0.041077558,0.00048128245,0.004253585,0.0033924226],"study_design_scores_gemma":[0.010290834,0.0049491203,0.9336466,0.00014447405,0.005787261,0.000002221441,0.0035569903,0.032042094,0.00747028,0.00004725725,0.0019029455,0.00015988485],"about_ca_topic_score_codex":0.25698242,"about_ca_topic_score_gemma":0.6812501,"teacher_disagreement_score":0.42426765,"about_ca_system_score_codex":0.0014350673,"about_ca_system_score_gemma":0.0013876597,"threshold_uncertainty_score":0.7479654},"labels":[],"label_agreement":null},{"id":"W4386387581","doi":"10.1007/s11523-023-00987-1","title":"Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial","year":2023,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"National Cancer Institute; Ono Pharmaceutical; Memorial Sloan-Kettering Cancer Center; Bristol-Myers Squibb","keywords":"Nivolumab; Medicine; Ipilimumab; Renal cell carcinoma; Placebo; Nephrectomy; Internal medicine; Adjuvant; Oncology; Adjuvant therapy; Kidney cancer; Clinical trial; Cancer; Surgery; Immunotherapy; Kidney; Pathology; Alternative medicine","score_opus":0.12948190054941494,"score_gpt":0.4061370170159111,"score_spread":0.27665511646649615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386387581","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9731466,0.0026867497,0.00022105932,0.00079194293,0.0016332488,0.01521273,0.00017365727,0.0002549028,0.005879077],"genre_scores_gemma":[0.98044455,0.00021410023,0.00257718,0.00009116631,0.0009080499,0.008176319,0.0010426538,0.00015398368,0.006391986],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9934477,0.0014164973,0.00155507,0.001023574,0.0010713267,0.0014858271],"domain_scores_gemma":[0.99287623,0.0043649,0.00047806144,0.00093608384,0.0007643797,0.00058037165],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0041848156,0.0005768373,0.0029277634,0.0012901889,0.0001960681,0.000026817903,0.00036194996,0.00066905253,0.0007114696],"category_scores_gemma":[0.0007241075,0.00047356545,0.0009997744,0.0012780947,0.0009073537,0.000115310024,0.00027870646,0.0008029089,0.00024680758],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9729884,0.0015404915,0.000026512476,0.0005006477,0.00064366317,0.0016942284,0.00112127,0.000039202576,0.0061148982,0.000069950445,0.013692332,0.001568364],"study_design_scores_gemma":[0.9187047,0.01941757,0.000018185838,0.000092894705,0.001304079,0.0000456092,0.0004491053,0.0029389486,0.03391765,0.00021571931,0.022540756,0.00035478646],"about_ca_topic_score_codex":0.00061140483,"about_ca_topic_score_gemma":0.0001675277,"teacher_disagreement_score":0.05428374,"about_ca_system_score_codex":0.0015589142,"about_ca_system_score_gemma":0.0025793328,"threshold_uncertainty_score":0.9997716},"labels":[],"label_agreement":null},{"id":"W4387032788","doi":"10.1007/s11523-023-01000-5","title":"A Systematised Literature Review of Real-World Treatment Patterns and Outcomes in Unresectable Advanced or Metastatic Biliary Tract Cancer","year":2023,"lang":"en","type":"review","venue":"Targeted Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"AstraZeneca","keywords":"Medicine; Observational study; Gemcitabine; Cochrane Library; Internal medicine; MEDLINE; Chemotherapy; Cancer; Biliary tract cancer; Oncology; Intensive care medicine; Meta-analysis","score_opus":0.08894734557234671,"score_gpt":0.4349304150010871,"score_spread":0.34598306942874035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387032788","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015639585,0.99299943,5.488014e-7,0.0003958788,0.00033785417,0.0047791414,0.0009310538,0.000060280938,0.00033939435],"genre_scores_gemma":[0.00007172084,0.99209994,0.00016141929,0.000222141,0.000079871206,0.0032770298,0.0004581373,0.00008571103,0.0035440123],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9966377,0.0005322728,0.0015123602,0.00063091656,0.00024567227,0.00044108334],"domain_scores_gemma":[0.9973014,0.0011653239,0.0007632425,0.0005033652,0.00012611644,0.00014055659],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003896098,0.0006377137,0.0074644005,0.000661762,0.00003698922,0.000009146161,0.00013399617,0.00021110554,0.0001805396],"category_scores_gemma":[0.00024526476,0.00035815357,0.00052814826,0.0012247977,0.00006460693,0.00006125225,0.00007968666,0.00041514408,0.000008853263],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001161555,0.00032893923,0.0037865397,0.6490956,0.001753317,0.0018481761,0.0004348892,1.5400197e-7,6.999631e-7,0.000007878759,0.0009064229,0.34172124],"study_design_scores_gemma":[0.0031030313,0.0015591269,0.007728439,0.6165014,0.007304468,0.00023834548,0.000114419105,0.000002270426,0.0000015831703,0.000006325857,0.363048,0.00039262683],"about_ca_topic_score_codex":0.0017975902,"about_ca_topic_score_gemma":0.011861221,"teacher_disagreement_score":0.36214158,"about_ca_system_score_codex":0.0011190071,"about_ca_system_score_gemma":0.0011953561,"threshold_uncertainty_score":0.99988705},"labels":[],"label_agreement":null},{"id":"W4387930721","doi":"10.1007/s11523-023-00997-z","title":"A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","year":2023,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Cetuximab; Medicine; Internal medicine; Head and neck squamous-cell carcinoma; Oncology; Head and neck cancer; Phases of clinical research; Cancer; Clinical trial; Colorectal cancer","score_opus":0.03311622994514312,"score_gpt":0.33711391180749295,"score_spread":0.3039976818623498,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387930721","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99774295,0.00020647765,0.0000020175514,0.00021593833,0.000065248,0.0015109519,0.000014248135,0.000023886247,0.00021827088],"genre_scores_gemma":[0.9994711,0.00001629534,0.00018235088,0.000067676505,0.0000075361445,0.00014117615,0.00005026092,0.000018138126,0.000045443052],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987243,0.00014630849,0.00035547596,0.0002804807,0.00021936277,0.00027408986],"domain_scores_gemma":[0.99939114,0.00015714199,0.0001210912,0.00014079006,0.00011837332,0.000071487426],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001915665,0.00015403295,0.0007094927,0.000366742,0.000030960407,0.000002538118,0.00004326696,0.000043976615,0.000015593485],"category_scores_gemma":[0.00006619061,0.00010167732,0.000012695072,0.0008034289,0.0000670223,0.000048388174,0.000038815717,0.00018622869,0.0000029409007],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019882113,0.042842884,0.90556556,0.00036248995,0.000052438223,0.0005748317,0.01677986,0.000012664826,0.000091357964,0.0000059310987,0.00041714168,0.013412711],"study_design_scores_gemma":[0.14801332,0.11704615,0.73062235,0.000071671806,0.000098027216,0.0000039915285,0.0035130924,0.00029239937,0.0000873509,0.000008303023,0.00013504722,0.000108285676],"about_ca_topic_score_codex":0.00049228634,"about_ca_topic_score_gemma":0.0056342483,"teacher_disagreement_score":0.17494322,"about_ca_system_score_codex":0.00017679945,"about_ca_system_score_gemma":0.00021794185,"threshold_uncertainty_score":0.41462806},"labels":[],"label_agreement":null},{"id":"W4392654691","doi":"10.1007/s11523-024-01034-3","title":"Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC","year":2024,"lang":"en","type":"letter","venue":"Targeted Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada); Princess Margaret Cancer Centre; University Health Network","funders":"AstraZeneca","keywords":"Osimertinib; Medicine; Lung cancer; Oncology; Internal medicine; Placebo; Epidermal growth factor receptor; Stage (stratigraphy); Cancer; Pathology; Erlotinib; Biology","score_opus":0.05860293502871478,"score_gpt":0.41327494089060063,"score_spread":0.35467200586188585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392654691","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.042618074,0.0059588943,0.000009655209,0.8336922,0.0016166068,0.0032733358,0.00057317514,0.00030632952,0.11195174],"genre_scores_gemma":[0.2660829,0.0018765817,0.0042901877,0.49373397,0.010449134,0.002637031,0.036995504,0.001313388,0.18262129],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963957,0.0006267311,0.00066644035,0.00072056893,0.0007770609,0.00081348734],"domain_scores_gemma":[0.99778867,0.0007966255,0.00018521766,0.0005498812,0.0005576245,0.00012200181],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0005387332,0.0003630721,0.0011269216,0.0012362888,0.00005745647,0.000015701517,0.00020854881,0.0010975348,0.00058243674],"category_scores_gemma":[0.00019862609,0.00026967595,0.00013331098,0.0012282177,0.00043513585,0.0000548556,0.00010519852,0.0035606648,0.00011354051],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017435952,0.00036791002,0.0013220742,0.0008183856,0.0012152444,0.014326088,0.0009776804,0.000009627731,0.0010883181,0.000072322655,0.9772144,0.0008443289],"study_design_scores_gemma":[0.0066531133,0.004587006,0.00476775,0.0015479346,0.00080427434,0.00013896106,0.00021017152,0.000056316672,0.000421778,0.0006128612,0.979879,0.00032081906],"about_ca_topic_score_codex":0.0026088043,"about_ca_topic_score_gemma":0.00075138867,"teacher_disagreement_score":0.33995822,"about_ca_system_score_codex":0.0014347029,"about_ca_system_score_gemma":0.0033655555,"threshold_uncertainty_score":0.99997556},"labels":[],"label_agreement":null},{"id":"W4393260725","doi":"10.1007/s11523-024-01046-z","title":"Palbociclib in Older Patients with Advanced/Metastatic Breast Cancer: A Systematic Review","year":2024,"lang":"en","type":"review","venue":"Targeted Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"Pfizer","keywords":"Palbociclib; Medicine; Breast cancer; Randomized controlled trial; Population; Metastatic breast cancer; Clinical trial; Oncology; Internal medicine; Cochrane Library; Cancer","score_opus":0.01904652755948039,"score_gpt":0.3726052928173543,"score_spread":0.35355876525787394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393260725","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000008219356,0.9875009,0.00001821902,0.0004022144,0.0004722731,0.010755286,0.0005040405,0.0001788336,0.00016003582],"genre_scores_gemma":[0.000015259195,0.9896883,0.000740845,0.0012756571,0.00012071866,0.006838881,0.0004861807,0.00027765098,0.0005565155],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9952031,0.0005565082,0.0018899408,0.0010137692,0.0005370835,0.000799606],"domain_scores_gemma":[0.9971908,0.00030189386,0.0010857004,0.0008764153,0.00028123977,0.00026399316],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003870018,0.0010325114,0.008891428,0.0005581289,0.000042340856,0.000014924111,0.00034938948,0.0003358122,0.000520232],"category_scores_gemma":[0.00012119877,0.00062793173,0.0005419663,0.0016054258,0.00017709086,0.00013575258,0.000109747496,0.0012788747,0.0003295558],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000078820034,0.00028341956,0.00002151238,0.6856462,0.0008133145,0.00030627937,0.000065180306,7.202185e-7,5.2015295e-8,0.000014614569,0.0003061198,0.3124638],"study_design_scores_gemma":[0.00218852,0.00042549707,0.000049953487,0.7680913,0.015379649,0.0007696668,0.000025896423,0.0000016718159,4.0993246e-8,0.00003263458,0.21252668,0.00050848926],"about_ca_topic_score_codex":0.000021660435,"about_ca_topic_score_gemma":0.000056467332,"teacher_disagreement_score":0.3119553,"about_ca_system_score_codex":0.0024926732,"about_ca_system_score_gemma":0.0019738148,"threshold_uncertainty_score":0.9996172},"labels":[],"label_agreement":null},{"id":"W4399799341","doi":"10.1007/s11523-024-01076-7","title":"Safety and Preliminary Efficacy of Once-Weekly Split-Dose Selinexor in Soft Tissue Sarcoma: Results of the Phase Ib METSSAR Clinical Trial","year":2024,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Karyopharm Therapeutics","keywords":"Medicine; Tolerability; Nausea; Adverse effect; Internal medicine; Clinical endpoint; Phases of clinical research; Vomiting; Clinical trial; Toxicity; Anorexia; Oncology; Surgery","score_opus":0.06135130984307056,"score_gpt":0.42116634898864436,"score_spread":0.3598150391455738,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399799341","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.976857,0.010613116,0.000016563125,0.009274933,0.00073814683,0.001748718,0.00013416394,0.000040081934,0.0005772799],"genre_scores_gemma":[0.9968664,0.00082120486,0.0015178216,0.00017944603,0.00029310246,0.00003447535,0.000075838725,0.000023962986,0.00018773334],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9972666,0.00047684606,0.0013077987,0.00046164566,0.00022737366,0.0002597439],"domain_scores_gemma":[0.9959398,0.0031495984,0.0002488422,0.00046349215,0.00007210038,0.00012620275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012963163,0.00019312494,0.0009866267,0.00012260056,0.000037061873,0.0000046746004,0.0001436481,0.00029883755,0.00010043154],"category_scores_gemma":[0.0013971926,0.00012658497,0.00021706132,0.00032232245,0.0003652353,0.000034816258,0.00013059333,0.00040200228,0.000016670117],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25828117,0.017308265,0.004458533,0.00020366306,0.000537245,0.0009931498,0.0015805954,0.000017817534,0.0017857691,0.00027831653,0.008638841,0.70591664],"study_design_scores_gemma":[0.5076086,0.043251358,0.2528019,0.00073203986,0.0017435955,0.00024430838,0.00033740804,0.0028229791,0.0046447134,0.0003608414,0.18514515,0.00030713825],"about_ca_topic_score_codex":0.00028750312,"about_ca_topic_score_gemma":0.00009656314,"teacher_disagreement_score":0.7056095,"about_ca_system_score_codex":0.00011076001,"about_ca_system_score_gemma":0.00049844955,"threshold_uncertainty_score":0.5161986},"labels":[],"label_agreement":null},{"id":"W4400327380","doi":"10.1007/s11523-024-01074-9","title":"A Podcast on Platinum Eligibility and Treatment Sequencing in Platinum-Eligible Patients with Locally Advanced or Metastatic Urothelial Carcinoma","year":2024,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Carboplatin; Metastatic Urothelial Carcinoma; Pembrolizumab; Oncology; Internal medicine; Cisplatin; Chemotherapy; Nivolumab; Avelumab; Atezolizumab; Urothelial carcinoma; Immunotherapy; Cancer; Bladder cancer","score_opus":0.029661348170795524,"score_gpt":0.32597582500551686,"score_spread":0.29631447683472134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400327380","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942355,0.00049755606,0.000066037006,0.0002606698,0.00021040913,0.001850697,0.00016355787,0.00011466688,0.0026009043],"genre_scores_gemma":[0.99597615,0.000056605793,0.0025285752,0.00043841527,0.00007868801,0.00027549083,0.00010435298,0.000055192293,0.0004865448],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99806875,0.00011391587,0.00041803555,0.0006784235,0.00025708007,0.000463812],"domain_scores_gemma":[0.9991016,0.00027978868,0.00007100544,0.00027591398,0.000071287344,0.00020040342],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001202761,0.0003666337,0.00069009897,0.0002486366,0.00006763618,0.000023594983,0.000055986944,0.000121347155,0.00023068319],"category_scores_gemma":[0.000059481263,0.00022663696,0.00006469822,0.00035380985,0.00011362887,0.0001061372,0.000026820764,0.00024864255,0.00004272036],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08318335,0.0043560727,0.42687407,0.0011205806,0.0020293512,0.011129858,0.01665256,0.0014135826,0.0087806955,0.0005932934,0.00061400223,0.44325256],"study_design_scores_gemma":[0.16265318,0.22986309,0.53624403,0.0025064533,0.0027777413,0.001031009,0.00313424,0.010925766,0.023775555,0.0018947434,0.022796022,0.002398186],"about_ca_topic_score_codex":0.0009693079,"about_ca_topic_score_gemma":0.0014926615,"teacher_disagreement_score":0.44085437,"about_ca_system_score_codex":0.002772538,"about_ca_system_score_gemma":0.002186014,"threshold_uncertainty_score":0.9241987},"labels":[],"label_agreement":null},{"id":"W4403977769","doi":"10.1007/s11523-024-01102-8","title":"Adavosertib in Combination with Olaparib in Patients with Refractory Solid Tumors: An Open-Label, Dose-Finding, and Dose-Expansion Phase Ib Trial","year":2024,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Cancer Institute; AstraZeneca","keywords":"Medicine; Olaparib; Maximum tolerated dose; Open label; Refractory (planetary science); Oncology; Solid tumor; Internal medicine; Clinical trial; Cancer","score_opus":0.04736721586451495,"score_gpt":0.3932493215087382,"score_spread":0.3458821056442233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403977769","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953721,0.00030812187,0.0000453358,0.0005598791,0.0003601155,0.0023884866,0.00002284123,0.000098394725,0.00084473286],"genre_scores_gemma":[0.99745667,0.000048651214,0.00092095934,0.00058769085,0.00011687832,0.00029427974,0.0004119539,0.00005870688,0.00010421091],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99782443,0.0002975633,0.0005493316,0.0006087988,0.0003353266,0.00038454434],"domain_scores_gemma":[0.99910504,0.00014146438,0.00017626765,0.00027944567,0.000120992736,0.00017678381],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005576173,0.00025659293,0.0006612406,0.00052718155,0.00006859771,0.000054466294,0.00014430856,0.0002406728,0.00017432094],"category_scores_gemma":[0.00005644666,0.00020154657,0.000013195281,0.0006173435,0.00016313489,0.00057958515,0.000052258772,0.00060032896,0.000011480359],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.76151735,0.041037604,0.039665822,0.0003788258,0.00028975663,0.0017818453,0.010038875,0.00006630912,0.03827224,0.0010552111,0.0026963311,0.10319983],"study_design_scores_gemma":[0.7865131,0.13592742,0.06188533,0.0013718194,0.00011013673,0.000052524018,0.0004562224,0.0017609779,0.002260846,0.0004626954,0.00861908,0.0005798321],"about_ca_topic_score_codex":0.0002043127,"about_ca_topic_score_gemma":0.0005107737,"teacher_disagreement_score":0.10262,"about_ca_system_score_codex":0.0008688731,"about_ca_system_score_gemma":0.00081630563,"threshold_uncertainty_score":0.8218831},"labels":[],"label_agreement":null},{"id":"W4404024879","doi":"10.1007/s11523-024-01111-7","title":"Durvalumab Following Chemoradiotherapy for Stage III Non-small Cell Lung Cancer: Differences in Survival Based on Age and Post-Progression Systemic Therapy","year":2024,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia; University of Victoria","funders":"AstraZeneca","keywords":"Medicine; Durvalumab; Chemoradiotherapy; Stage (stratigraphy); Oncology; Systemic therapy; Lung cancer; Internal medicine; Cancer; Pathology; Immunotherapy","score_opus":0.021619840625903716,"score_gpt":0.32708693537086064,"score_spread":0.3054670947449569,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404024879","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96288157,0.031426653,0.0003710811,0.0013759095,0.0015460739,0.0018825157,0.00005681872,0.00011218074,0.0003472235],"genre_scores_gemma":[0.99395674,0.0029819424,0.00051771535,0.0009953172,0.00021983591,0.00048573446,0.000073470605,0.000061245664,0.0007079839],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99828655,0.00014138674,0.00041430094,0.00052555784,0.00020344736,0.0004287338],"domain_scores_gemma":[0.99910474,0.00042885228,0.000103072016,0.0002203996,0.00004514397,0.000097796226],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006022924,0.00029379645,0.0007763236,0.00028631804,0.000093969196,0.000043215936,0.00012178289,0.00028889635,0.00014000345],"category_scores_gemma":[0.000015096546,0.0002201629,0.00021845345,0.00028930185,0.00008034671,0.00005040903,0.000013508694,0.00027246683,0.0000010834077],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02539829,0.0006223256,0.042235292,0.001956106,0.0005432815,0.0009859779,0.0039523803,0.0000282805,0.8025211,0.000027587357,0.00063131005,0.121098064],"study_design_scores_gemma":[0.22151147,0.04134141,0.31515518,0.01392116,0.0009545745,0.00013300018,0.00619163,0.22549248,0.12167833,0.00007286698,0.050039712,0.0035081967],"about_ca_topic_score_codex":0.0006351239,"about_ca_topic_score_gemma":0.00022595437,"teacher_disagreement_score":0.68084276,"about_ca_system_score_codex":0.0005685231,"about_ca_system_score_gemma":0.0006530057,"threshold_uncertainty_score":0.89779824},"labels":[],"label_agreement":null},{"id":"W4406352769","doi":"10.1007/s11523-024-01126-0","title":"Buparlisib and Paclitaxel in Patients with Head and Neck Squamous Cell Carcinoma: Immunogenomic Biomarkers of Efficacy from the BERIL-1 Study","year":2025,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Paclitaxel; Head and neck; Head and neck squamous-cell carcinoma; Basal cell; Internal medicine; Oncology; Carcinoma; Head and neck cancer; Chemotherapy; Radiation therapy; Surgery","score_opus":0.010648178780210604,"score_gpt":0.27467149228984566,"score_spread":0.26402331350963504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406352769","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911042,0.006243971,9.117491e-7,0.0004993839,0.00011456505,0.0010178436,0.000035222172,0.000011631415,0.00097230455],"genre_scores_gemma":[0.9994565,0.000040397983,0.00013894992,0.00024586587,0.000017897748,0.000031362513,0.00001848567,0.000011175633,0.000039355873],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99895376,0.0001380908,0.00030756462,0.00028689275,0.00009512223,0.00021855166],"domain_scores_gemma":[0.9991219,0.0004424869,0.000085885695,0.00023742752,0.00006246729,0.000049851176],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015704431,0.00015442725,0.00059206784,0.000090695605,0.00007782515,0.0000044973885,0.00007034637,0.00008249222,0.000014466572],"category_scores_gemma":[0.000070796144,0.00009910976,0.00002450934,0.0002138558,0.00021708831,0.00002308172,0.0001084985,0.00016631934,0.0000011061035],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035128742,0.0011811359,0.9863645,0.00003702402,0.0001243156,0.000018216733,0.0037465508,5.942315e-7,0.0009951292,0.000003406947,0.00043849775,0.0035777732],"study_design_scores_gemma":[0.021477101,0.005228142,0.96973777,0.000037318518,0.00017880149,8.2931257e-7,0.0023733512,0.0000071940426,0.00022031531,0.000013184956,0.0006424159,0.00008359611],"about_ca_topic_score_codex":0.003406701,"about_ca_topic_score_gemma":0.0013439074,"teacher_disagreement_score":0.017964227,"about_ca_system_score_codex":0.00011591772,"about_ca_system_score_gemma":0.00017977318,"threshold_uncertainty_score":0.51499355},"labels":[],"label_agreement":null},{"id":"W4406484983","doi":"10.1007/s11523-024-01123-3","title":"Bosutinib for the Treatment of CML—Using it Safely: a Podcast","year":2025,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Pfizer","keywords":"Medicine; Bosutinib; Oncology; Bioinformatics; Cancer research; Dasatinib; Imatinib","score_opus":0.050757151797893,"score_gpt":0.38388280706674194,"score_spread":0.33312565526884896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406484983","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93926936,0.009268949,0.0035778699,0.021102738,0.0017480005,0.005132581,0.00016539471,0.0001262741,0.019608852],"genre_scores_gemma":[0.98141515,0.0005444806,0.008502195,0.0014143629,0.00026931037,0.00028788374,0.00009316434,0.000029651474,0.0074437847],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99892646,0.00005109494,0.00036063505,0.00024874846,0.00009579842,0.0003172372],"domain_scores_gemma":[0.9985945,0.0007151829,0.00013141605,0.00039221774,0.000107628184,0.00005903473],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012538806,0.00017226631,0.00052598264,0.00011358092,0.00010815662,0.0000034734994,0.00009261834,0.00016454469,0.0002632842],"category_scores_gemma":[0.000113233495,0.000109786175,0.00019572832,0.00023104857,0.00013684448,0.000017497907,0.000025154195,0.00008314685,0.000012741308],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013536068,0.011187778,0.023496004,0.00070731825,0.009458895,0.00040261904,0.008235363,0.0005876986,0.103544846,0.007397165,0.049564004,0.77188224],"study_design_scores_gemma":[0.023133727,0.006535377,0.006359738,0.0001095946,0.0020574436,0.00009692601,0.0008588134,0.0063839615,0.025919953,0.00041353065,0.92797613,0.00015478434],"about_ca_topic_score_codex":0.00033274337,"about_ca_topic_score_gemma":0.00013455962,"teacher_disagreement_score":0.8784121,"about_ca_system_score_codex":0.0023948182,"about_ca_system_score_gemma":0.0016585905,"threshold_uncertainty_score":0.6262366},"labels":[],"label_agreement":null},{"id":"W4410569892","doi":"10.1007/s11523-025-01146-4","title":"Olaparib Monotherapy or in Combination with Abiraterone for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) and a BRCA Mutation","year":2025,"lang":"en","type":"review","venue":"Targeted Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"AstraZeneca","keywords":"Medicine; Olaparib; Abiraterone; Prostate cancer; Oncology; PARP inhibitor; Internal medicine; Docetaxel; Cancer; BRCA mutation; Ovarian cancer; Poly ADP ribose polymerase; Androgen receptor","score_opus":0.04601313563003731,"score_gpt":0.3846335911876247,"score_spread":0.33862045555758735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410569892","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00774233,0.97875667,0.00048296087,0.00041693298,0.00013432257,0.011713548,0.0007022199,0.000024576288,0.000026415579],"genre_scores_gemma":[0.0018827207,0.986869,0.0018592372,0.000110776156,0.00002712964,0.00795483,0.0008690401,0.000047265956,0.0003800399],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99844104,0.0001891405,0.0006282583,0.00035010083,0.00017796761,0.00021351273],"domain_scores_gemma":[0.9981377,0.00069539493,0.00063448754,0.00020738589,0.00028019855,0.000044838824],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014300231,0.00032903807,0.0014074497,0.00025913538,0.000068615824,0.0000121293015,0.000054201064,0.0001308659,0.000052124],"category_scores_gemma":[0.000017618062,0.00016314948,0.000072635754,0.00042932978,0.00015367453,0.0000575117,0.0000039070433,0.00011569383,4.1818114e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012573936,0.0016097197,0.00029076182,0.00761174,0.0012732038,0.000025777783,0.0016466839,0.000052294006,0.0000122075835,0.00008230214,0.00007844187,0.97474295],"study_design_scores_gemma":[0.08790901,0.058595046,0.004569127,0.014554626,0.0068056174,0.000038494174,0.00038427935,0.00021928218,0.00019324692,0.00017755467,0.82589626,0.0006574315],"about_ca_topic_score_codex":0.00026382538,"about_ca_topic_score_gemma":0.0020041612,"teacher_disagreement_score":0.9740855,"about_ca_system_score_codex":0.0010012008,"about_ca_system_score_gemma":0.0018897891,"threshold_uncertainty_score":0.6653043},"labels":[],"label_agreement":null},{"id":"W4411010011","doi":"10.1007/s11523-025-01154-4","title":"A Phase I Study of the Anti-CEACAM6 Antibody Tinurilimab (BAY 1834942) in Patients with Advanced Solid Tumors","year":2025,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Radiopharmaceutical Chemistry and Applications","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Bayer","keywords":"Medicine; Antibody; Bay; Solid tumor; Cancer research; Oncology; Internal medicine; Immunology; Cancer","score_opus":0.010978016127561923,"score_gpt":0.37808912529642613,"score_spread":0.3671111091688642,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411010011","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99449813,0.000054232318,0.00002141683,0.0008972273,0.000056361576,0.0011562759,0.000011418727,0.000025874278,0.0032790876],"genre_scores_gemma":[0.9990555,0.0000035056412,0.0001296287,0.00047600197,0.000017567148,0.00007461226,0.000026054699,0.000011026539,0.00020608728],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989523,0.00007044521,0.0003577417,0.00025736907,0.00014252249,0.00021960263],"domain_scores_gemma":[0.99929565,0.00006720074,0.00012534087,0.00034555257,0.000103882885,0.00006239721],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000105430445,0.00012570417,0.00042306926,0.000062842475,0.000048826936,0.000002182667,0.00015390587,0.00007766311,0.00005293445],"category_scores_gemma":[0.00009269431,0.00008360582,0.000039534007,0.0005985472,0.00014180283,0.000027602777,0.000049224098,0.00031709543,0.0000046805885],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005091405,0.061299864,0.694797,0.00026938584,0.0003033211,0.00006698444,0.0012000873,0.00016196449,0.22870898,0.00019140496,0.0007959063,0.0071136896],"study_design_scores_gemma":[0.07662194,0.0064736945,0.8196675,0.00022234695,0.00040359393,0.000009186276,0.0013226644,0.00035446737,0.08712829,0.00012491792,0.00742718,0.00024420794],"about_ca_topic_score_codex":0.0000075060625,"about_ca_topic_score_gemma":0.000004516498,"teacher_disagreement_score":0.1415807,"about_ca_system_score_codex":0.000097254204,"about_ca_system_score_gemma":0.00017434404,"threshold_uncertainty_score":0.34093463},"labels":[],"label_agreement":null},{"id":"W4411055081","doi":"10.1007/s11523-025-01153-5","title":"Circulating Tumor DNA in Advanced EGFRex20+ NSCLC: Concordance with Tissue Biopsy, Monitoring of Response, and Resistance to High-Dose Osimertinib","year":2025,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Newfoundland and Labrador; AstraZeneca","keywords":"Medicine; Osimertinib; Concordance; Acquired resistance; Biopsy; Oncology; Circulating tumor DNA; Pathology; Internal medicine; Cancer; Adenocarcinoma","score_opus":0.006775695507202522,"score_gpt":0.2802244547159031,"score_spread":0.2734487592087006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411055081","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951422,0.0024114624,0.0006718727,0.0005493937,0.00025662343,0.00035555608,0.000033899818,0.000010081424,0.00056887744],"genre_scores_gemma":[0.9824583,0.000094391056,0.016780227,0.00023252498,0.00008200469,0.000074187796,0.000014256639,0.00001967594,0.00024443405],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99876016,0.00009910459,0.00034839544,0.00043045584,0.000074229414,0.00028764474],"domain_scores_gemma":[0.9991544,0.00019144178,0.0001480262,0.00031055344,0.00011665233,0.00007892838],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025530317,0.00016494718,0.0003270762,0.00011995131,0.000052516727,0.000009102005,0.00015494133,0.00011694437,0.000003937951],"category_scores_gemma":[0.0005027063,0.00017231313,0.000021897236,0.00030635667,0.000115278235,0.0000043042287,0.00012625252,0.00010978296,0.0000010611436],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043983576,0.000048021408,0.020106498,0.000042611067,0.000028025252,0.00005790396,0.00012375247,0.00040266523,0.9695062,0.00024947245,0.0001226579,0.0049138255],"study_design_scores_gemma":[0.0032273394,0.0012393841,0.21662049,0.00023622283,0.00002619632,0.000018506744,0.00032306885,0.000014493878,0.7550409,0.0003050796,0.022646742,0.00030157733],"about_ca_topic_score_codex":0.000088772846,"about_ca_topic_score_gemma":0.00039814852,"teacher_disagreement_score":0.2144653,"about_ca_system_score_codex":0.000092455666,"about_ca_system_score_gemma":0.00039154943,"threshold_uncertainty_score":0.70267254},"labels":[],"label_agreement":null},{"id":"W4415817417","doi":"10.1007/s11523-025-01182-0","title":"Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON Study","year":2025,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Loxo Oncology; Eli Lilly Japan; Chugai Pharmaceutical; Genentech; Grifols; Casen Recordati; Japanese Society of Medical Oncology; Pfizer Japan; Sociedad Española de Oncología Médica; Shionogi; Astellas Pharma; Eisai; Seagen; Lunit; Johnson and Johnson; Les Laboratories Pierre Fabre; Verily Life Sciences; BeiGene; Mirati Therapeutics; Ipsen; Five Prime Therapeutics; Boehringer Ingelheim Japan; Taiho Pharmaceutical; Puma Biotechnology; Regeneron Pharmaceuticals; Yuhan; Daiichi Sankyo Europe; LEO Pharma; Gilead Sciences; Sanofi; Pfizer; Innovent Biologics; Bristol-Myers Squibb; Ono Pharmaceutical; Eli Lilly and Company; AstraZeneca; Amgen; Mesothelioma Applied Research Foundation","keywords":"Lung cancer; Exon; Phases of clinical research; Epidermal growth factor receptor; Cell; Cancer","score_opus":0.013197917408025058,"score_gpt":0.38700755247232627,"score_spread":0.3738096350643012,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415817417","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929682,0.0022589117,0.00005383039,0.00053388113,0.0000794918,0.002014905,0.00016273452,0.0000173053,0.0019107457],"genre_scores_gemma":[0.9973316,0.00034677892,0.00018938759,0.0007062371,0.000040762778,0.00038873844,0.000044719534,0.000020532238,0.0009312399],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99907935,0.000075987744,0.00027696847,0.0002833158,0.00007425441,0.00021009905],"domain_scores_gemma":[0.99934393,0.0001527449,0.00012749172,0.00026008495,0.00005760997,0.00005815984],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000065495515,0.0001995221,0.000460088,0.000100963305,0.000076158554,0.000009723445,0.000059054113,0.00008640447,0.00031522554],"category_scores_gemma":[0.0000061332316,0.00010843734,0.000065169785,0.00023328495,0.00008844287,0.00003627344,0.000016451866,0.000108296845,0.0000013511919],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0063977833,0.006063522,0.9454127,0.000023107637,0.0019371483,0.00005918042,0.018435562,0.00013946477,0.012394455,0.000007494974,0.0006873462,0.008442235],"study_design_scores_gemma":[0.14063759,0.013515141,0.8271316,0.00023544456,0.0019208987,0.0000064421815,0.0043309308,0.0009089683,0.007311663,0.00007797311,0.003694794,0.00022849799],"about_ca_topic_score_codex":0.031915493,"about_ca_topic_score_gemma":0.011428546,"teacher_disagreement_score":0.13423981,"about_ca_system_score_codex":0.0011989038,"about_ca_system_score_gemma":0.00084057375,"threshold_uncertainty_score":0.97453105},"labels":[],"label_agreement":null},{"id":"W4416937861","doi":"10.1007/s11523-025-01187-9","title":"Tebentafusp in Metastatic Uveal Melanoma: A Meta-analysis","year":2025,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Ocular Oncology and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Standard of care; MEDLINE; Patient care; Neoplasm staging; Overall survival","score_opus":0.049363425699247745,"score_gpt":0.3741072122374792,"score_spread":0.3247437865382315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416937861","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83827615,0.017661495,0.0016248277,0.023785323,0.0006191925,0.0022485016,0.000075261996,0.00022697312,0.11548228],"genre_scores_gemma":[0.98615044,0.000027668219,0.0051581822,0.0025437106,0.000014174224,0.00020178923,0.00013789308,0.000010190933,0.0057559754],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9982826,0.0003812108,0.000458078,0.00039776415,0.00012903562,0.0003512956],"domain_scores_gemma":[0.99908096,0.00029867646,0.00010569496,0.00035562707,0.00006356278,0.00009549503],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00041257383,0.00020294749,0.0017502094,0.0008795787,0.00005696973,0.0000046924297,0.00010303348,0.00020514791,0.0024056262],"category_scores_gemma":[0.00012005614,0.00015326636,0.00080489647,0.001460791,0.000109029526,0.000042782867,0.000055905217,0.0002963568,0.00015755324],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011766809,0.005049452,0.2650328,0.00008491095,0.7067606,0.005790392,0.0005147441,0.00016320292,0.000736518,0.0061878297,0.003568446,0.00493444],"study_design_scores_gemma":[0.009205165,0.001730405,0.13111113,0.000004471968,0.8125602,0.00008652634,0.00031080484,0.0005517324,0.001159557,0.0035811,0.039451376,0.00024754164],"about_ca_topic_score_codex":0.0003076789,"about_ca_topic_score_gemma":0.0017255549,"teacher_disagreement_score":0.14787427,"about_ca_system_score_codex":0.00035921307,"about_ca_system_score_gemma":0.00042436417,"threshold_uncertainty_score":0.9985063},"labels":[],"label_agreement":null},{"id":"W4417274131","doi":"10.1007/s11523-025-01186-w","title":"Idasanutlin in Combination with Chemotherapy or Venetoclax in Pediatric and Young Adult Patients with Relapsed/Refractory Solid Tumors (iMATRIX Idasa): Results of a Phase I/II, Multicenter, Multi-arm Study","year":2025,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); Alberta Children's Hospital","funders":"Genentech; Roche","keywords":"Young adult; Chemotherapy; Venetoclax; Phases of clinical research; Solid tumor","score_opus":0.01157666888915094,"score_gpt":0.3287658524750596,"score_spread":0.31718918358590864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417274131","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958847,0.00009805208,0.00011213673,0.00019558797,0.00009821633,0.0034124623,0.000030648356,0.000041341573,0.00012683685],"genre_scores_gemma":[0.99750125,0.00012089043,0.0016136069,0.00016603919,0.000028713079,0.00019300579,0.000094499504,0.000042014606,0.00023998732],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99718356,0.00030939904,0.00092647463,0.00060278736,0.00046708365,0.00051071664],"domain_scores_gemma":[0.9981808,0.00043547613,0.00038587232,0.00035902817,0.0004959209,0.0001429061],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005355217,0.00030524263,0.0008735686,0.0010507528,0.00008961003,0.000007834848,0.00017980188,0.00023633508,0.000017524388],"category_scores_gemma":[0.0007756669,0.0002202213,0.000030618114,0.0012819861,0.00019385634,0.0001324124,0.00013868712,0.0005826995,0.0000018983598],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.103521295,0.032910634,0.8484727,0.0003067711,0.00015886496,0.0005939678,0.009294133,0.00006993258,0.000546548,0.000005515997,0.00025174458,0.0038678735],"study_design_scores_gemma":[0.3472647,0.041864563,0.59422463,0.00028209595,0.00013947692,0.000012516335,0.0017638823,0.013705742,0.000469015,0.000005235371,0.000048140068,0.00021997392],"about_ca_topic_score_codex":0.00115927,"about_ca_topic_score_gemma":0.002786492,"teacher_disagreement_score":0.25424808,"about_ca_system_score_codex":0.0021329753,"about_ca_system_score_gemma":0.0019477176,"threshold_uncertainty_score":0.8980365},"labels":[],"label_agreement":null}]}